Ovarian abstracts

755 abstracts

Abstract Ovarian cancer risk factors in relation to family history Congress:ESMO 2024, Search all connections
Abstract Ovarian function suppression in premenopausal patients with concurrent endocrine therapy use. Congress:ASCO 2021, Search all connections
Abstract Ovarian cancer mortality: implications of income-inequality and availability of medical doctors in Brazil. Congress:ASCO 2022, Search all connections
Abstract Ovarian cancer: Age, prognosis, and biologic underpinnings. Congress:ASCO 2022, Search all connections
Abstract Ovarian function suppression is not indispensable in patients with early breast cancer who are older than age 40. Congress:ASCO 2022, Search all connections
Abstract Ovarian cancer and bevacizumab: Real-world use across western countries and effect on survival in high-risk subgroups. Organization:AstraZeneca,Portuguese Institute...,Champalimaud Foundat...,Drug:bevacizumab, Search all connections
Abstract Ovarian-Adnexal Reporting & Data System (O-RADS) versus modified benign descriptors and IOTA ADNEX (two-step strategy) in classification of ovarian masses. Organization:Fundación Santa Fé d...,Fundacion Santa Fe d...,Universidad de los A...,Congress:ASCO 2024, Search all connections
Abstract Integrative proteomic profiling in high-grade serous ovarian carcinoma: Unraveling biomarkers and therapeutic targets Congress:ESMO 2024, Search all connections
Abstract Poly (ADP-Ribose) polymerase inhibitors (PARPI): Associated thrombosis in patients with ovarian cancer Congress:ESMO 2024, Search all connections
Abstract Perceptions of genetic testing and lived experiences in women with locally advanced or metastatic ovarian cancer: A focus on BRCAm and BRCAwt patients Congress:ESMO 2024, Search all connections
Abstract Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD) Congress:ESMO 2024, Search all connections
Abstract AI enabled intervention increased real-world guideline compliant care: Improving genomic testing and cascade genetics for women with ovarian cancer (OC) Congress:ESMO 2024, Search all connections
Abstract Ex vivo basket study reports patient-specific sensitivity to carboplatin versus cisplatin in lung, ovarian and bladder cancer Congress:ESMO 2024, Search all connections
Abstract Organoid growth-based oncological sensitivity test (OncoSensi) for predicting adjuvant therapy outcomes in ovarian cancer patients Congress:ESMO 2024, Search all connections
Abstract Stereotactic radiotherapy alone or followed by niraparib for oligometastases or oligoprogression in ovarian cancer following PARP inhibitor therapy: SOPRANO trial Congress:ESMO 2024, Search all connections
Abstract Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS) Congress:ESMO 2024, Search all connections
Abstract The differences in immunogenicity of TP53 mutated endometrial-, high-grade serous ovarian- and triple negative breast carcinomas Congress:ESMO 2024, Search all connections
Abstract ESCAT gene actionability detection in early-stage ovarian: A descriptive analysis of an Italian referral center Congress:ESMO 2024, Search all connections
Abstract Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer (PSROC) and a BRCA mutation (C-PATROL): Overall survival (OS) in predefined subgroups Congress:ESMO 2024, Search all connections
Abstract Propensity-score matching analysis for efficacy of platinum-based versus non-platinum chemotherapy in patients with â€œplatinum-resistantâ€� ovarian cancer (PROC): Real-world recent cohort study Congress:ESMO 2024, Search all connections
Abstract Testing unselected women with newly diagnosed high-grade serous ovarian cancer (HGSOC) for germline pathogenic variants (PVs) in mismatch repair (MMR) genes is unnecessary Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety of pamiparib monotherapy in recurrent ovarian cancer (rOC) after prior PARPi exposure: A prospective, open label, single-arm, phase II study Congress:ESMO 2024, Search all connections
Abstract A phase II study of the efficacy of olaparib maintenance monotherapy for patients with HRD-positive, newly diagnosed, advanced, high-grade ovarian cancer, evaluated by whole-exome sequencing (MSBM-OL) Congress:ESMO 2024, Search all connections
Abstract Liquid biopsy for the determination of homologous recombination deficiency in patients with high-grade serous ovarian cancer: Results of the BOVARY-pilot study Congress:ESMO 2024, Search all connections
Abstract Association between chemotherapy response score (CRS) and tumour homologous recombination deficiency (tHRD) in women with newly diagnosed FIGO stage IIIC/IV high-grade serous ovarian cancer (HGSOC) Congress:ESMO 2024, Search all connections
Abstract Initial management and long-term outcome of ovarian clear cell carcinoma (OCCC) in the French multicentre ESME database Congress:ESMO 2024, Search all connections
Abstract Role of tumor primary chemosensitivity assessed by modeled CA-125 KELIM to predict complete interval debulking surgery (IDS) in ovarian carcinoma patients treated with neo-adjuvant chemotherapy and immunotherapy: A GINEGEPS/GINECO study of the NeoPembrOv and INeOV trials Congress:ESMO 2024, Search all connections
Abstract Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA mutation (C-PATROL): Analysis by BRCA mutation status from a real-world study Congress:ESMO 2024, Search all connections
Abstract Claudin-6 expression in primary and recurrent epithelial ovarian cancer: A potential therapeutic target for high-grade serous ovarian cancer Congress:ESMO 2024, Search all connections
Abstract Neoadjuvant pembrolizumab in stage IV ovarian cancer: The phase II Neo-Pembro trial Congress:ESMO 2024, Search all connections
Abstract Reclassification and variant distribution in the GINECO GREAT study of ovarian cancer patients: Insights into HRD status Congress:ESMO 2024, Search all connections
Abstract A phase II trial of fuzuloparib in combination with apatinib vs. fuzuloparib alone for recurrent ovarian cancer (OC) Congress:ESMO 2024, Search all connections
Abstract HER2 expression in ovarian cancer: Its relationship with HRD status, and other biomarkers Congress:ESMO 2024, Search all connections
Abstract How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in platinum sensitive recurrent ovarian cancer and long-term outcomes Congress:ESMO 2024, Search all connections
Abstract Re-VOLVE: Phase II trial in women with ovarian cancer progressing post-PARP-inhibitor with treatment adapted to real-time assessment of evolving genomic resistance Congress:ESMO 2024, Search all connections
Abstract First results from phase II dose expansion cohort of transcon IL-2 Î²/Î³ in combination with standard of care chemotherapy for platinum resistant ovarian cancer (PROC) in the IL Believe trial Congress:ESMO 2024, Search all connections
Abstract Anti-angiogenic therapy in first-line treatment of low-grade serous ovarian cancer: Exploratory meta-analysis of the prospective AGO-OVAR 11/12/16 studies Congress:ESMO 2024, Search all connections
Abstract Cadonilimab with neoadjuvant chemotherapy in advanced ovarian cancer patients (AK104-IIT-003): An open, prospective, single arm, phase II trial Congress:ESMO 2024, Search all connections
Abstract JSKN003, a HER2-targeting antibody-drug conjugate, in patients with platinum-resistant ovarian cancer: A pooled analysis of two studies Congress:ESMO 2024, Search all connections
Abstract Results of the phase Ib study of NC410 combined with pembrolizumab in ovarian cancer patients Congress:ESMO 2024, Search all connections
Abstract Sustained long-term responders to niraparib maintenance in recurrent platinum-sensitive high-grade ovarian cancer (PSROC): A subanalysis of the GEICO-88R study Congress:ESMO 2024, Search all connections
Abstract Final analysis of KGOG3046/TRU-D: A phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer Congress:ESMO 2024, Search all connections
Abstract Beyond HRD status: Unraveling genetic variants impacting PARP inhibitor sensitivity in advanced ovarian cancer Congress:ESMO 2024, Search all connections
Abstract Initial results from a first-in-human study of AZD5335, a folate receptor Î± (FRÎ±)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC) Congress:ESMO 2024, Search all connections
Abstract Unlocking the circulating immune landscape of advanced clear-cell ovarian cancer: Insights from the MOCCA trial Congress:ESMO 2024, Search all connections
Abstract Clinical and molecular predictors of outcome in patients with tubo-ovarian high-grade serous carcinoma and exceptional survival Congress:ESMO 2024, Search all connections
Abstract Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial Congress:ESMO 2024, Search all connections
Abstract Phase I safety and efficacy of brenetafusp, a PRAME Ã— CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC) Congress:ESMO 2024, Search all connections
Abstract Luveltamab tazevibulin, an antifolate receptor alpha (FRÎ±) antibody-drug conjugate (ADC), in combination with bevacizumab (bev) in patients with recurrent high-grade epithelial ovarian cancer (EOC): STRO-002-GM2 phase I study Congress:ESMO 2024, Search all connections
Abstract Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients with ARID1A-mutated ovarian clear cell carcinoma Congress:ESMO 2024, Search all connections
Abstract SOLACE2: A phase II randomized trial of olaparib (O) and durvalumab (D) with or without low dose cyclophosphamide (LDCy) in platinum-sensitive recurrent ovarian cancer (PSROC) Congress:ESMO 2024, Search all connections
Abstract Phase III MIRASOL trial: Updated overall survival results of mirvetuximab soravtansine (MIRV) vs. investigatorâ€™s choice chemotherapy (ICC) in patients (pts) with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRÎ±) expression Congress:ESMO 2024, Search all connections
Abstract Biomarker-driven targeted therapy in platinum-resistant ovarian cancer (BRIGHT): An open-label, multicenter, umbrella trial Congress:ESMO 2024, Search all connections
Abstract A phase II study of ACR-368 in patients with ovarian (OvCa) or endometrial carcinoma (EnCa) and prospective validation of OncoSignature patient selection (NCT05548296) Congress:ESMO 2024, Search all connections
Abstract Determination of the most common hereditary mutations associated with breast cancer and ovarian cancer in the population of Ukrainian women Congress:ESMO 2024, Search all connections
Abstract Impact of pembrolizumab on ovarian function in young triple negative breast cancer patients treated with chemo-immunotherapy Congress:ESMO 2024, Search all connections
Abstract GynePDX: A new platform of preclinical models for endometrial and ovarian cancers Congress:ESMO 2024, Search all connections
Abstract Role of plasma exosomes in crosstalk between immune system and hereditary ovarian cancer: Opportunity or challenge? Congress:ESMO 2024, Search all connections
Abstract Association of homologous recombination deficiency status with outcomes for ovarian cancer patients treated with olaparib, and exploration of other biomarkers of relapse and survival Congress:ESMO 2024, Search all connections
Abstract Use of biosimulation to predict homologous recombination deficiency and PARPi benefit in patients with ovarian, pancreatic, prostate and triple negative breast cancers Congress:ESMO 2024, Search all connections
Abstract NGS-based identification of novel hereditary breast/ovarian cancer genes in patients with clinical features of genetic predisposition Congress:ESMO 2024, Search all connections
Abstract ASSESSMENT OF OVARIAN RESERVE WITH ANTI-MÜLLERIAN HORMONE IN FEMALE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS Organization:Department of Rheuma...,Congress:EULAR 2014, Search all connections
Abstract ASSESSMENT OF OVARIAN RESERVE IN PREMENOPAUSAL PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS Organization:Hospital de Clínicas...,Congress:EULAR 2015, Search all connections
Abstract ANTI-MÜLLERIAN HORMONE LEVELS IN FEMALE RHEUMATOID ARTHRITIS PATIENTS TRYING TO CONCEIVE – THE ROLE OF OVARIAN FUNCTION IN TIME TO PREGNANCY IN A NATIONWIDE COHORT STUDY Organization:Division of Reproduc...,Department of Rheuma...,Department of Intern...,Congress:EULAR 2017, Search all connections
Abstract ANALYSIS OF OVARIAN DYSFUNCTION AND RELATED SEROLOGICAL INDICATORS IN SSc Organization:Peking University Th...,Congress:EULAR 2024, Search all connections
Abstract The impact of chemotherapy on sleep quality in women undergoing cytotoxic treatment for breast, ovarian, and endometrial cancer. Congress:ASCO 2019, Search all connections
Abstract Risk of secondary hematologic malignancies and tolerability in patients with ovarian cancer treated with PARP inhibitors: A systematic review and meta-analysis of four phase III randomized controlled trials. Congress:ASCO 2019, Search all connections
Abstract Feasibility of text-based symptom monitoring of ovarian and endometrial patients during treatment. Congress:ASCO 2019, Search all connections
Abstract Gastrointestinal symptoms and diagnosis preceding ovarian cancer diagnosis: Delays in diagnosis and resulting effects on treatment allocation. Congress:ASCO 2019, Search all connections
Abstract EMR documentation of genetics evaluations in patients with ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract Genetic testing for hereditary breast and ovarian cancer in Indian population: A single institutional study. Congress:ASCO 2019, Search all connections
Abstract BRCA1/2 and multigene panel testing among metastatic breast, pancreas, prostate, and ovarian cancer patients. Congress:ASCO 2019, Search all connections
Abstract Germline genetic testing in ovarian cancer patients: Identifying barriers to care and opportunities for improvement. Congress:ASCO 2019, Search all connections
Abstract Non-interventional study OVATAR final report: Diagnostic and treatment approaches in Russian ovarian cancer population—BRCAm group analysis. Congress:ASCO 2019, Search all connections
Abstract A non-interventional, multicenter study to assess prevalence of BRCA1 and BRCA2 mutation among ovarian, primary peritoneal, and fallopian tube cancer patients in India. Congress:ASCO 2019, Search all connections
Abstract Assessment of breast cancer risk in BRCA carriers with ovarian cancer: Evaluation of data from longitudinal observation. Congress:ASCO 2019, Search all connections
Abstract Results of NGS panel of hereditary breast and ovarian cancer in Lebanese women. Congress:ASCO 2019, Search all connections
Abstract Real-world duration of maintenance therapy in 2nd-line and later ovarian cancer (OC). Congress:ASCO 2019, Search all connections
Abstract Clinical outcomes of postoperative intraperitoneal chemotherapy for patients with early-stage high-grade serous ovarian cancer (HGSC) treated at British Columbia cancer agency. Congress:ASCO 2019, Search all connections
Abstract Identification of prognostic variables in advanced ovarian cancer based on real-world patients from big data analytics. Congress:ASCO 2019, Search all connections
Abstract Half-dose olaparib reduction: Safe and efficient dose in multi-treated Mexican ovarian cancer patients. Congress:ASCO 2019, Search all connections
Abstract Predictive factors of cytoreductive surgery in epithelial ovarian cancer in a Mexican women cohort. Congress:ASCO 2019, Search all connections
Abstract Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis. Congress:ASCO 2019, Search all connections
Abstract Dynamic of molecular subtypes of high‐grade serous ovarian cancer in paired primary and relapsed biopsies. Congress:ASCO 2019, Search all connections
Abstract The role of macrophage production of transforming growth factor-ß in epithelial ovarian cancer progression. Congress:ASCO 2019, Search all connections
Abstract Clinical benefit of bevacizumab in Mexican ovarian cancer patients according to the intention of treatment by the oncologist. Congress:ASCO 2019, Search all connections
Abstract Association between time to first subsequent therapy (TFST) and overall survival (OS) in previously untreated patients with ovarian cancer (OC): A SEER Medicare database analysis. Congress:ASCO 2019, Search all connections
Abstract Clinicopathologic features and prognostic analysis of stage I ovarian clear cell cancer. Congress:ASCO 2019, Search all connections
Abstract Hypermetabolic activity by FDG-PET after immunogenic chemotherapy and multi-peptide immunotherapy in ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract Poly adenosine diphosphate ribose polymerase inhibitors maintenance in patients with ovarian cancer: A systematic review and meta-analysis of randomized controlled trials. Congress:ASCO 2019, Search all connections
Abstract The effects of Wnt inhibition on tumor progression and the tumor microenvironment in a syngeneic mouse model of ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract New biomarkers to predict platinum resistance in ovarian cancer patients. Congress:ASCO 2019, Search all connections
Abstract CD49d (high) T cells in the ovarian cancer microenvironment are a potential target for the optimization of immune checkpoint therapy in ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract Mutational landscape of ovarian cancers (OC) identified by prospective clinical sequencing in a nationwide cancer network. Congress:ASCO 2019, Search all connections
Abstract Prognosis of ovarian cancer in the United States during 1973 to 2015. Congress:ASCO 2019, Search all connections
Abstract Factors associated with one-year mortality after debulking surgery in older women with ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract Increasing potency and safety of anticancer drugs through sortilin receptor-mediated cancer therapy: A new targeted approach for the treatment of ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract The developmental origins of high grade serous ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract Prognostic value of monocyte to lymphocyte ratio (MLR) in epithelial ovarian cancer (EOC). Congress:ASCO 2019, Search all connections
Abstract Factors associated with extended survival for patients with platinum-resistant ovarian cancer treated with modified vaccinia oncolytic virotherapy. Congress:ASCO 2019, Search all connections
Abstract Bovine milk-derived exosomes mediated delivery of resibufogenin and its effect on platinum-resistant ovarian carcinoma. Congress:ASCO 2019, Search all connections
Abstract Clinical characteristics of clear cell ovarian cancer: A retrospective multicenter experience of 308 patients in South Korea. Congress:ASCO 2019, Search all connections
Abstract Effects of bevacizmab, eribulin and oxaliplatin in relapsed patients with platinum-resistant and refractory ovarian carcinomas: A preliminary case series with biomarker evaluation. Congress:ASCO 2019, Search all connections
Abstract Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery. Congress:ASCO 2019, Search all connections
Abstract FLABRA, frontline approach for BRCA testing in ovarian cancer (OC) treatment naïve population: A Latin America (LA) epidemiologic study. Congress:ASCO 2019, Search all connections
Abstract Telomere length and its implication as prognostic marker in ovarian cancer patients. Congress:ASCO 2019, Search all connections
Abstract The association of marital status, socioeconomic status, and race on the survival of ovarian cancer patients. Congress:ASCO 2019, Search all connections
Abstract Accuracy of primary laparoscopic staging in patients with early ovarian malignancies: A retrospective multicenter study. Congress:ASCO 2019, Search all connections
Abstract Delay in time to adjuvant chemotherapy and its impact on outcome in completely resected advanced ovarian malignancies treated with CRS, CRS+IP and CRS +HIPEC. Congress:ASCO 2019, Search all connections
Abstract Impact of a structured quality management program on survival of patients with advanced (AOC) and relapsed ovarian cancer (ROC) treated in a dedicated tertiary gynecologic-oncology (GO) center. Congress:ASCO 2019, Search all connections
Abstract Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: An institutional experience. Congress:ASCO 2019, Search all connections
Abstract Prognostic implications of lymph node metastasis in advanced ovarian cancer: Analysis of the National Cancer Database 2006 to 2014. Congress:ASCO 2019, Search all connections
Abstract Incorporation of HIPEC into a high volume ovarian cancer program: Initial results and outcomes. Congress:ASCO 2019, Search all connections
Abstract GPR30 signaling to regulate epithelial-mesenchymal transition and predict survival in ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract Selective and nonselective GR antagonists in combination with chemotherapy in ovarian cancer PDX models. Congress:ASCO 2019, Search all connections
Abstract Multiple genetic alterations to predict the clinical outcome for bevacizumab plus chemotherapy in advanced ovarian cancer: A retrospective study. Congress:ASCO 2019, Search all connections
Abstract Serum calretinin as a predictor for recurrence and overall survival in ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract Sarcopenia as a predictor of chemotherapy toxicity in patients with ovarian cancer receiving platinum and taxane-based chemotherapy. Congress:ASCO 2019, Search all connections
Abstract A phase I trial evaluating the safety and efficacy of weekly paclitaxel or cisplatin with electro-hyperthermia in patients with recurrent or persistent epithelial ovarian, fallopian tubal or primary peritoneal carcinoma (KGOG 3030). Congress:ASCO 2019, Search all connections
Abstract Visceral adiposity as a predictor of survival in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy. Congress:ASCO 2019, Search all connections
Abstract Sarcopenia as a predictor of survival in patients with epithelial ovarian cancer (EOC) receiving platinum and taxane-based chemotherapy. Congress:ASCO 2019, Search all connections
Abstract Effect of therapeutic GAS6/AXL inhibition of tumor and stromal cells on DNA damage and response to chemotherapy in ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract Nonclinical endpoint assessment utilizing a digital vivarium cloud platform in an ovarian cancer xenograft model. Congress:ASCO 2019, Search all connections
Abstract Direct oral anticoagulants (DOAC) versus warfarin and enoxaparin in ovarian vein thrombosis. Congress:ASCO 2019, Search all connections
Abstract BRCA 1/2 mutations in high-grade serous ovarian cancer (HGS-OC) patients of three Latin American countries: Report of 412 cases. Congress:ASCO 2019, Search all connections
Abstract The role of different TGFβ signatures in predicting outcome in high grade serous ovarian carcinoma. Congress:ASCO 2019, Search all connections
Abstract Genomic characterization of brain metastases (BM) in high-grade serous ovarian cancer (HGSOC). Congress:ASCO 2019, Search all connections
Abstract Somatic mutations in triple-negative breast carcinoma and high-grade serous ovarian carcinoma from young women. Congress:ASCO 2019, Search all connections
Abstract Use of ovarian suppression with endocrine therapy among premenopausal United States women with breast cancer, 2001-2016. Congress:ASCO 2019, Search all connections
Abstract Predictors and trajectories of fatigue in ovarian and uterine cancer. Congress:ASCO 2019, Search all connections
Abstract Germline mutation profile among Hispanic women with epithelial ovarian cancer (EOC). Congress:ASCO 2019, Search all connections
Abstract Comparison of risk-reducing surgery in women with BRCA and non-BRCA ovarian cancer susceptibility genes. Congress:ASCO 2019, Search all connections
Abstract Management of high, moderate, and low penetrance ovarian cancer susceptibility gene mutations: An assessment of current practice patterns. Congress:ASCO 2019, Search all connections
Abstract Prevalence and clinical implications of mismatch repair (MMR) deficiency in unselected non-serous epithelial ovarian cancer (EOC) patients (pts). Congress:ASCO 2019, Search all connections
Abstract Phase I (safety assessment) of durvalumab (MEDI4736) with focal sensitizing radiotherapy in platinum resistant ovarian, primary peritoneal or fallopian tube epithelial carcinoma. Congress:ASCO 2019, Search all connections
Abstract EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the HSP90 inhibitor ganetespib with carboplatin followed by maintenance treatment with niraparib (+/- ganetespib) compared to platinum-based combination-chemotherapy followed by niraparib in relapsed platinum-sensitive ovarian cancer patients. Congress:ASCO 2019, Search all connections
Abstract ENGOT-OV44/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC). Congress:ASCO 2019, Search all connections
Abstract ENGOT-Ov41/ GEICO-69-O/ ANITA trial: A phase III randomized, double-blinded trial of platinum-based chemotherapy (CT) with or without atezolizumab (ATZ) followed by niraparib maintenance with or without ATZ in patients with recurrent ovarian, tubal or peritoneal cancer (OC) and platinum treatment-free interval (TFIp) >6 months. Congress:ASCO 2019, Search all connections
Abstract ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208). Congress:ASCO 2019, Search all connections
Abstract DUO-O: A randomized Phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients. Congress:ASCO 2019, Search all connections
Abstract Elucidation of PARP inhibitor activity in BRCAwt recurrent ovarian cancer by hrr mutational gene profile analysis. Congress:ASCO 2019, Search all connections
Abstract Impact of the Affordable Care Act on early-stage diagnosis and treatment for women with ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract Clinical outcome of sequential chemotherapy after immune checkpoint inhibitors in advanced ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract Comprehensive genomic analysis of mucinous ovarian cancer reveals unique therapeutic vulnerabilities. Congress:ASCO 2019, Search all connections
Abstract Real-world data analysis of ovarian cancer (OC) maintenance utilization among maintenance eligible patients. Congress:ASCO 2019, Search all connections
Abstract Survival and clinical outcomes of ovarian cancer patients enrolled in phase I clinical trials. Congress:ASCO 2019, Search all connections
Abstract T cell trafficking within the peritoneal tumor environment and ovarian cancer progression. Congress:ASCO 2019, Search all connections
Abstract Tumor stroma proportion to predict platinum chemoresistance in primary ovarian carcinomas: A prospective study. Congress:ASCO 2019, Search all connections
Abstract Association of Ki67 expression levels and therapy outcome in low-grade serous ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract Real-world bevacizumab utilization and outcomes in first-line ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract Effect of estrogen and progesterone receptor expression on progression-free and overall survival outcomes in low-grade serous ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract BRCA tumor test in ovarian cancers: The changing role of molecular pathology in the era of PARP inhibitor (PARPi) therapy. Congress:ASCO 2019, Search all connections
Abstract Correlation of surgeon radiology assessment with laparoscopic scoring in patients with advanced-stage ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE1 trial): T cell responses and tumor infiltration correlate with tumor regression. Congress:ASCO 2019, Search all connections
Abstract Multi-parametric FDG PET/MRI as an early predictor of response to neoadjuvant chemotherapy in patients with epithelial ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract Real-life data: Women with recurrent platinum-sensitive ovarian cancer and BCARGEM treatment. Congress:ASCO 2019, Search all connections
Abstract Rethinking breast cancer surveillance in women with BRCA-associated ovarian cancer in the post-solo trial era. Congress:ASCO 2019, Search all connections
Abstract Real life efficacy and safety data of bevacizumab-based front line treatment in advance or metastatic ovarian cancer patients: Focus on patients with malignant ascites—A phase IV study. Congress:ASCO 2019, Search all connections
Abstract Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer (rOC)? A network meta-analysis (NMA). Congress:ASCO 2019, Search all connections
Abstract Impact of BRCA mutation status and time to platinum resistance on patients with advanced ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract Patient preferences for maintenance PARP therapy in ovarian cancer treatment. Congress:ASCO 2019, Search all connections
Abstract Cost-effectiveness analysis of laparoscopic disease assessment in ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. Congress:ASCO 2019, Search all connections
Abstract Risk factors for progression or death in ovarian cancer patients who completed first-line platinum treatment. Congress:ASCO 2019, Search all connections
Abstract Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial. Congress:ASCO 2019, Search all connections
Abstract How long have we got? The accuracy of physicians’ estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC). Congress:ASCO 2019, Search all connections
Abstract Recurrence of ovarian cancer in BRCAwt patients without maintenance therapy: Real-world evidence. Congress:ASCO 2019, Search all connections
Abstract Molecular stratification of endometrioid ovarian carcinomas. Congress:ASCO 2019, Search all connections
Abstract Bevacizumab beyond progression: Impact of subsequent bevacizumab retreatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression. Congress:ASCO 2019, Search all connections
Abstract Ofranergene obadenovec (VB-111) in platinum resistant ovarian cancer: Association of favorable response rates in a phase I/II study with an immunotherapeutic effect. Congress:ASCO 2019, Search all connections
Abstract Menopausal symptoms in epithelial ovarian cancer survivors: The GINECO VIVROVAIRE2 study. Congress:ASCO 2019, Search all connections
Abstract SOLO1 versus SOLO2: Cost-effectiveness of olaparib as maintenance therapy for newly diagnosed and platinum-sensitive recurrent ovarian carcinoma among women with germline BRCA mutations (gBRCAmut). Congress:ASCO 2019, Search all connections
Abstract Modeled CA-125 kinetics during neoadjuvant chemotherapy for predicting the likelihood of optimal interval debulking surgery in ovarian cancer patients: Data from CHIVA trial (a GINECO study). Congress:ASCO 2019, Search all connections
Abstract Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial. Congress:ASCO 2019, Search all connections
Abstract Omission of adjuvant therapy in stage I clear cell ovarian cancer: Review of the British Columbia (BC) cancer experience. Congress:ASCO 2019, Search all connections
Abstract Circulating tumor DNA analysis to reveal genomic profiles for epithelial ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract A randomized, double-blind, placebo-controlled phase Ib/II study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine (G) and carboplatin (C) versus GC for women with recurrent platinum-sensitive ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract Results of the VENUS study: Bevacizumab efficacy and safety in platinum-sensitive recurrent ovarian cancer (OC)—A real-life ambispective study. Congress:ASCO 2019, Search all connections
Abstract Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial. Congress:ASCO 2019, Search all connections
Abstract Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Congress:ASCO 2019, Search all connections
Abstract Relacorilant (RELA) with nab-paclitaxel (NP): Safety and activity in patients with pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer (OvCA). Congress:ASCO 2019, Search all connections
Abstract [18F] Fluciclatide PET as a biomarker of clinical response to combination therapy of pazopanib and paclitaxel in patients with platinum-resistant or platinum-refractory advanced ovarian cancer: Results of a phase Ib study. Congress:ASCO 2019, Search all connections
Abstract Anticancer activity in patients with advanced ovarian and biliary tract cancers treated with NUC-1031 and a platinum agent. Congress:ASCO 2019, Search all connections
Abstract Adoptive transfer of tumor-infiltrating lymphocytes in patients with sarcomas, ovarian, and pancreatic cancers. Congress:ASCO 2019, Search all connections
Abstract Tissue immune response in epithelial ovarian carcinoma. Congress:ASCO 2019, Search all connections
Abstract Response to immune checkpoint inhibition and survival in BRCA-associated recurrent ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial. Congress:ASCO 2019, Search all connections
Abstract Surveillance in stage I MOGCTs (malignant ovarian germ cell tumors): A MITO prospective study (multicenter Italian trials in ovarian cancer). Congress:ASCO 2019, Search all connections
Abstract Pembrolizumab with low dose carboplatin for recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer-interim results. Congress:ASCO 2019, Search all connections
Abstract Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study. Congress:ASCO 2019, Search all connections
Abstract Exploratory analysis of the effect of maintenance rucaparib on postprogression outcomes in patients (pts) with platinum-sensitive recurrent ovarian carcinoma (OC) and updated safety data from the phase 3 study ARIEL3. Congress:ASCO 2019, Search all connections
Abstract Evolve: A post PARP inhibitor clinical translational Phase II trial of cediranib-olaparib in ovarian cancer—A Princess Margaret Consortium – GCIG Phase II Trial. Congress:ASCO 2019, Search all connections
Abstract A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia. Congress:ASCO 2019, Search all connections
Abstract Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study. Congress:ASCO 2019, Search all connections
Abstract Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study. Congress:ASCO 2019, Search all connections
Abstract The prognosis of patients with recurrent or persistent ovarian clear cell carcinoma: Results from a randomized phase III study (JGOG3017/GCIG). Congress:ASCO 2019, Search all connections
Abstract Dose-dense early postoperative intraperitoneal chemotherapy in ovarian cancer: Randomized, phase II trial. Congress:ASCO 2019, Search all connections
Abstract A phase I study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC), or triple-negative breast cancer (TNBC). Congress:ASCO 2019, Search all connections
Abstract A phase II randomized study of avelumab plus entinostat versus avelumab plus placebo in patients (pts) with advanced epithelial ovarian cancer (EOC ). Congress:ASCO 2019, Search all connections
Abstract Results of a phase 2 trial of ribociclib and letrozole in patients with either relapsed estrogen receptor (ER)-positive ovarian cancers or relapsed ER-positive endometrial cancers. Congress:ASCO 2019, Search all connections
Abstract Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial. Congress:ASCO 2019, Search all connections
Abstract EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study. Congress:ASCO 2019, Search all connections
Abstract Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24. Congress:ASCO 2019, Search all connections
Abstract Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer. Congress:ASCO 2019, Search all connections
Abstract Anti-Müllerian hormone (AMH) as a marker of ovarian reserve and premature ovarian insufficiency (POI) in children and women with cancer: A systematic review. Congress:ASCO 2021, Search all connections
Abstract Real-world clinical practice: Toxicities of maintenance PARP inhibitors in recurrent ovarian cancer—The Royal Marsden experience. Congress:ASCO 2021, Search all connections
Abstract Do differences in baseline clinical severity of ovarian cancer patients with thrombosis predict treatment with rivaroxaban versus low molecular-weight heparin? Congress:ASCO 2021, Search all connections
Abstract Characterizing safety and efficacy in ovarian cancer patients with thromboembolism treated with rivaroxaban. Congress:ASCO 2021, Search all connections
Abstract Real-world patterns and predictors of first-line maintenance use among patients with newly diagnosed advanced ovarian cancer: Is there an opportunity for change? Congress:ASCO 2021, Search all connections
Abstract Real-world progression-free survival among patients with newly diagnosed advanced ovarian cancer: Does maintenance therapy work? Congress:ASCO 2021, Search all connections
Abstract Real-world data analysis of the utilization of second-line maintenance therapy for patients with advanced ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Measuring the impact and sustainability of a statewide program for identifying minority and underserved clients at risk for hereditary breast and ovarian cancer (HBOC): An eight-year follow up including transitions during the COVID pandemic. Congress:ASCO 2021, Search all connections
Abstract Epithelial ovarian cancer survival by race/ethnicity in an equal-access healthcare population. Congress:ASCO 2021, Search all connections
Abstract Use of the Utah population database to evaluate statewide use of genetic testing for hereditary breast/ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Genetic and clinical characterization of multigene hereditary breast and ovarian cancer (HBOC) panels in Málaga (Spain). Congress:ASCO 2021, Search all connections
Abstract Performance characteristics of brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed ovarian cancers. Congress:ASCO 2021, Search all connections
Abstract The impact of live education on the competence and performance of oncology practitioners who care for patients with ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Using 3D perfusion bioreactor system to studying cell biology of ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Homologous recombination deficiency associated with response to poly (ADP-ribose) polymerase inhibitors in ovarian cancer patients: The first real-word data from China. Congress:ASCO 2021, Search all connections
Abstract Feasibility of ovarian preservation as a stage in correcting the quality of life in young patients after gynecologic surgeries. Congress:ASCO 2021, Search all connections
Abstract Functional status of patients suffering from ovarian cancer: A cross-sectional study. Congress:ASCO 2021, Search all connections
Abstract Upregulation of HSPB1 heat shock gene and ERCC1 gene on serous ovarian cancer cell line in HIPEC in vitro model. Congress:ASCO 2021, Search all connections
Abstract Evaluation of immunohistochemical expression of mismatch repair proteins in endometrioid and seromucinous borderline ovarian tumors a 10-year experience in a large health care institution. Congress:ASCO 2021, Search all connections
Abstract Retrospective analysis of ovarian cancer patients treated with PARP inhibitors. Congress:ASCO 2021, Search all connections
Abstract Is age-related worsening in ovarian cancer prognosis linked to changes in body composition and pharmacokinetics? Congress:ASCO 2021, Search all connections
Abstract Laboratory cross-comparison of homologous recombination repair mutation analysis in tumor in a multicenter epithelial ovarian cancer series: The BORNEO GEICO 60-0 study. Congress:ASCO 2021, Search all connections
Abstract Efficacy and safety of weekly paclitaxel in elderly patients with heavily pretreated platinum-resistant ovarian carcinoma. Congress:ASCO 2021, Search all connections
Abstract The role of polymorphisms occurring in BRCA1/2 genes in determining ovarian cancer risk. Congress:ASCO 2021, Search all connections
Abstract Identification of signal transduction pathway activity with potential clinical target in high-grade serous ovarian and tubal carcinoma. Congress:ASCO 2021, Search all connections
Abstract Final survival follow-up and translational associations using interval indirect immunization with oregovomab (O) and poly ICLC in patients (pts) with recurrent platinum-resistant ovarian cancer (PROC). Congress:ASCO 2021, Search all connections
Abstract Integrating the genomic and TCR repertoire signatures predicts prognosis in primary epithelial ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Tumor infiltrating lymphocytes (TILs) in endometrioid and clear cell ovarian carcinoma: Characterization, association with mismatch repair system deficiency and endometriosis, and prognostic implications. Congress:ASCO 2021, Search all connections
Abstract Classification of molecular subtypes of high-grade serous ovarian cancer by MALDI-Imaging. Congress:ASCO 2021, Search all connections
Abstract Stem-like markers in the circulating tumor cells assessment in ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Preliminary results of anlotinib and niraparib dual therapy evaluation in platinum-resistant recurrent ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Variance of HRD score from primary to recurrent in high-grade serous ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Determinants of response to checkpoint inhibition in ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Chemotherapy response score: Validation of a three-tier system to quantify histopathologic response to neoadjuvant chemotherapy in ovarian carcinoma. Congress:ASCO 2021, Search all connections
Abstract Impact on survival of surgical therapeutic strategy in the initial management of advanced ovarian cancer: A study from the Cote d’Or gynaecological cancer registry from 1998 to 2015. Congress:ASCO 2021, Search all connections
Abstract IL-17A and CCL2 in blood serum and circulating neutrophils in patients with ovarian tumors. Congress:ASCO 2021, Search all connections
Abstract Factors of VEGF, IGF, and TGF-β1 families in omentum tissues to mark premetastatic niches in ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Impact of pleural effusion in ovarian cancer: A retrospective study in Lleida, Spain. Congress:ASCO 2021, Search all connections
Abstract Mutational profiles of ovarian cancer in Chinese patients revealed potential therapeutic targets and prognostic markers. Congress:ASCO 2021, Search all connections
Abstract Frequency of homologous recombination repair alterations in ovarian cancer in Chinese population. Congress:ASCO 2021, Search all connections
Abstract Expression of multidrug resistance marker MDR1 in patients with ovarian cancer and its possible predictive significance. Congress:ASCO 2021, Search all connections
Abstract L-MOCA: An open-label study of olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Integrative genomic and transcriptomic analysis reveals prognostic markers and immune subtype in Chinese ovarian clear cell carcinoma. Congress:ASCO 2021, Search all connections
Abstract Levels of some cytokines in tumors of ovarian cancer patients with different responses to platinum-containing chemotherapy. Congress:ASCO 2021, Search all connections
Abstract Amount of cancer stem cells in tumors of patients with ovarian cancer with different responses to platinum-containing chemotherapy. Congress:ASCO 2021, Search all connections
Abstract Investigating reasons for discontinuation of first-line adjuvant chemotherapy among ovarian cancer patients in the midwestern United States. Congress:ASCO 2021, Search all connections
Abstract Anlotinib in patients with recurrent platinum-resistant or refractory ovarian carcinoma: A prospective, single-arm, single-center, phase II clinical study. Congress:ASCO 2021, Search all connections
Abstract Propensity score matching analysis of ovarian cancer patients with multiple primary malignant neoplasms using multicenter real-world data. Congress:ASCO 2021, Search all connections
Abstract Anti-tumor activity of SKLB-0322, a novel EZH2 covalent inhibitor, in ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Effect of Wnt pathway inhibitor on ovarian cancer tumors. Congress:ASCO 2021, Search all connections
Abstract Modification of intrinsic ovarian cancer tumor factors by Wnt-pathway agents influences macrophage recruitment and activity. Congress:ASCO 2021, Search all connections
Abstract Feasibility and patient perception of a web-based exercise program during COVID pandemic in breast and ovarian cancer patients. Congress:ASCO 2021, Search all connections
Abstract Predicting 180-day mortality for women with ovarian cancer using machine learning and patient-reported outcome data. Congress:ASCO 2021, Search all connections
Abstract Family history of breast and/or ovarian cancer (FHBOC) as an independent prognostic factor in triple negative breast cancer overall survival. Congress:ASCO 2021, Search all connections
Abstract Trends in use of ovarian suppression (OS) for premenopausal patients with early-stage hormone positive breast cancer and Intermediate Risk (IR) Oncotype Recurrence Scores (RS) from 2006-2020: A retrospective database analysis. Congress:ASCO 2021,ASCO 2020, Search all connections
Abstract Associations between patient-centered communication and quality of life in patients with ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Testing for mutations in BRCA1 and BRCA2 among ovarian cancer patients at a diverse academic medical center. Congress:ASCO 2021, Search all connections
Abstract Genetic assessment of hereditary breast and ovarian cancer in the Harris Health System: A five-year, single-center experience. Congress:ASCO 2021, Search all connections
Abstract Germline testing and somatic tumor testing for BRCA1/2 pathogenic variants in ovarian cancer: What is the optimal sequence of testing? Congress:ASCO 2021, Search all connections
Abstract A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB500-OC-004). Congress:ASCO 2021, Search all connections
Abstract FLORA-5: Front-line chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab [PCO] versus chemotherapy (Paclitaxel-Carboplatin-Placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III double-blind placebo controlled multinational study. Congress:ASCO 2021, Search all connections
Abstract Uplift (ENGOT-ov67): A pivotal cohort to evaluate XMT-1536 (upifitamab rilsodotin), a NaPi2b-directed antibody drug conjugate for platinum-resistant ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract ROCSAN trial (GINECO-EN203b/ENGOT-EN8): A multicentric randomized phase II/III evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of endometrial/ovarian carcinosarcoma after at least one line of platinum based chemotherapy. Congress:ASCO 2021, Search all connections
Abstract ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC). Congress:ASCO 2021, Search all connections
Abstract A phase I/II, multicenter, open-label study of REGN5668 (mucin [MUC]16 x CD28 bispecific antibody [bsAb]) with cemiplimab (programmed death [PD]-1 Ab) or REGN4018 (MUC16 x CD3 bsAb) in recurrent ovarian cancer (rOVCA). Congress:ASCO 2021, Search all connections
Abstract ENGOT-ov54/Swiss-GO-2/MATAO including LOGOS (Low-Grade Ovarian cancer Sub-study): MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer—A randomized, double-blinded, placebo-controlled, multicenter phase III Trial. Congress:ASCO 2021, Search all connections
Abstract Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018). Congress:ASCO 2021, Search all connections
Abstract Final results of phase 1 evaluation of the safety and clinical activity of sapanisertib in combination with serabelisib and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer. Congress:ASCO 2021, Search all connections
Abstract Correlation of HRD status with clinical and survival outcomes in patients with advanced-stage ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Assessment of predictive biomarker prevalence in molecularly defined adult-type ovarian granulosa cell tumors. Congress:ASCO 2021, Search all connections
Abstract Phase 1b study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma. Congress:ASCO 2021, Search all connections
Abstract Improving the prediction of surgical outcome at secondary cytoreduction in patients with ovarian cancer: Results from retrospective part of HELP-ER study NOGGO TR2/ENGOT OV47-TR. Congress:ASCO 2021, Search all connections
Abstract Outcomes of ovarian cancer patients treated with platinum or non-platinum based chemotherapy after PARP inhibitor maintenance. Congress:ASCO 2021, Search all connections
Abstract Anlotinib in combination with TQB2450 in patients with recurrent ovarian cancer (ACTION): A multicenter, single-arm, open-label, phase Ib trial. Congress:ASCO 2021, Search all connections
Abstract Real-life data of niraparib maintenance treatment in patients with recurrent platinum-sensitive ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Symptom identification and management in epithelial ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Does aggressive surgery only benefit patients with less advanced ovarian cancer? Congress:ASCO 2021, Search all connections
Abstract Association of the Khorana Score with development of venous thromboembolism in ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Next generation sequencing in ovarian cancer patients: Does personalized medicine improve oncological outcomes? Congress:ASCO 2021, Search all connections
Abstract Disparities in ovarian cancer treatment and overall survival according to race: An update. Congress:ASCO 2021, Search all connections
Abstract Serum-based assay for adnexal mass risk of ovarian malignancy. Congress:ASCO 2021, Search all connections
Abstract Phase 1 dose-escalation study of STRO-002, an antifolate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced, progressive platinum-resistant/refractory epithelial ovarian cancer (EOC). Congress:ASCO 2021, Search all connections
Abstract Circulating tumor DNA as a noninvasive marker of resectability in ovarian carcinomas. Congress:ASCO 2021, Search all connections
Abstract Health-related quality of life (QoL) in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD), a multicenter single-arm phase II clinical trial (ROLANDO, GEICO-1601). Congress:ASCO 2021, Search all connections
Abstract Feasibility of an adapted schedule of carboplatin plus paclitaxel in elderly women with advanced ovarian cancer: A retrospective cohort. Congress:ASCO 2021, Search all connections
Abstract Nanoanalysis of plasma volatile organic compounds using novel DNA-decorated carbon nanotube vapor sensors to noninvasively distinguish ovarian and pancreatic cancer from benign and control samples. Congress:ASCO 2021, Search all connections
Abstract Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION primary analysis. Congress:ASCO 2021, Search all connections
Abstract The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma. Congress:ASCO 2021, Search all connections
Abstract Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC). Congress:ASCO 2021, Search all connections
Abstract Postoperative adjuvant dose-dense chemotherapy with bevacizumab and maintenance bevacizumab after neoadjuvant chemotherapy for advanced ovarian cancer: A phase II AGOG/TGOG trial. Congress:ASCO 2021, Search all connections
Abstract Patient self-reporting of tolerability using PRO-CTCAE: A randomized double-blind placebo controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in women with platinum resistant epithelial ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in patients (Pts) with selected frα-positive solid tumors: Results in the ovarian cancer (EC) cohort. Congress:ASCO 2021, Search all connections
Abstract Underutilization of germline BRCA testing in commercially-insured women diagnosed with ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract LIO-1: Lucitanib + nivolumab in patients with advanced solid tumors—Updated phase 1b results and initial experience in phase 2 ovarian cancer cohort. Congress:ASCO 2021, Search all connections
Abstract Safety assessment of niraparib individualized starting dose in patients with platinum-sensitive recurrent ovarian cancer: A randomized, double-blind, placebo-controlled, phase III NORA trial. Congress:ASCO 2021, Search all connections
Abstract Association of homologous recombination deficiency in ovarian cancer with neoantigen load and expression of immune checkpoints. Congress:ASCO 2021, Search all connections
Abstract Anlotinib plus pemetrexed as a further treatment for patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study. Congress:ASCO 2021, Search all connections
Abstract Efficacy of niraparib maintenance therapy in Chinese women with platinum-sensitive recurrent ovarian cancer with and without secondary cytoreductive surgery: Results from the NORA trial. Congress:ASCO 2021, Search all connections
Abstract Differential benefit from fractionated dose-dense first-line chemotherapy for epithelial ovarian cancer (EOC) according to KELIM-evaluated tumor primary chemosensitivity: Exploratory analyses of ICON-8 trial. Congress:ASCO 2021, Search all connections
Abstract An international, multicenter, real-world analysis of epithelial ovarian cancer treatment and outcomes. Congress:ASCO 2021, Search all connections
Abstract Development of extracellular vesicles-based classifier for detection of early-stage bladder, ovarian, and pancreatic cancer. Congress:ASCO 2021, Search all connections
Abstract Genome-wide 5hmC profiles to enable cancer detection and tissue of origin classification in breast, colorectal, lung, ovarian, and pancreatic cancers. Congress:ASCO 2021, Search all connections
Abstract Use of a high-sensitivity anti-Mullerian hormone (AMH) assay to determine ovarian function after chemotherapy for early breast cancer. Congress:ASCO 2021, Search all connections
Abstract Health concerns in long-term survivors with ovarian cancer: Results of Expression VI–Carolin meets HANNA–Holistic Analysis of Long-term survival with Ovarian Cancer—The international NOGGO, ENGOT and GCIG survey. Congress:ASCO 2021, Search all connections
Abstract Cancer-specific mortality associated with germline genetic testing results among women with breast cancer or ovarian cancer treated with chemotherapy. Congress:ASCO 2021, Search all connections
Abstract Limitations of direct-to-consumer (DTC) genetic testing for hereditary breast and ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib/placebo maintenance in the phase III PAOLA-1/ENGOT-ov25 trial. Congress:ASCO 2021, Search all connections
Abstract Niraparib efficacy and safety in patients with BRCA mutated (BRCAm) ovarian cancer: Results from three phase 3 niraparib trials. Congress:ASCO 2021, Search all connections
Abstract Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4. Congress:ASCO 2021, Search all connections
Abstract Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study. Congress:ASCO 2021, Search all connections
Abstract Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC). Congress:ASCO 2021, Search all connections
Abstract Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study. Congress:ASCO 2021, Search all connections
Abstract An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer (KGOG 3045, AMBITION). Congress:ASCO 2021, Search all connections
Abstract Dendritic cell vaccine (DCVAC) combined with chemotherapy (CMT) in patients with newly diagnosed epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Biomarker exploratory analysis of a phase 2, open-label, randomized, multicenter trial. Congress:ASCO 2021, Search all connections
Abstract Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Final analysis of the PROMISE-GIM6 phase III trial assessing GnRH agonist use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with early breast cancer. Congress:ASCO 2021, Search all connections
Abstract Phase 3, randomized, single-dose, open-label study to investigate the safety and efficacy of pafolacianine sodium injection (OTL38) for intraoperative imaging of folate receptor positive ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer. Congress:ASCO 2021, Search all connections
Abstract Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890). Congress:ASCO 2021, Search all connections
Abstract Maintenance vigil immunotherapy in newly diagnosed advanced ovarian cancer: Efficacy assessment of homologous recombination proficient (HRP) patients in the phase IIb VITAL trial. Congress:ASCO 2021, Search all connections
Abstract Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis. Congress:ASCO 2021, Search all connections
Abstract Real-world progression-free and overall survival for patients with advanced ovarian cancer utilizing PARP inhibitor second-line maintenance therapy vs active surveillance. Congress:ASCO 2022, Search all connections
Abstract Real-world use of PD-(L)1 immune checkpoint inhibitors (CPI) and post-CPI treatment patterns and outcomes in ovarian and endometrial cancer (2014-2021). Congress:ASCO 2022,ASCO 2021, Search all connections
Abstract Disparities in clinical trial participation in ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Disparities in biomarker testing in ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Profile and outcomes of patients with subsequent ovarian cancer diagnosis following a prior malignancy in the United States. Congress:ASCO 2022, Search all connections
Abstract Testing of newly diagnosed advanced high grade ovarian cancer (OC) patients with the Myriad Genetics MyChoice CDx Plus next generation sequencing-based in vitro diagnostic test emphasizes the need for public insurance coverage of genetic testing: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO). Congress:ASCO 2022, Search all connections
Abstract The impact of virtual live education on the competence and knowledge of gynecologists caring for ovarian cancer patients. Congress:ASCO 2022, Search all connections
Abstract Comparison of AYA versus non-AYA ovarian cancer genomic landscape in NCI-MATCH trial. Congress:ASCO 2022, Search all connections
Abstract Impact of paclitaxel versus docetaxel on neuropathy in ovarian cancer patients with diabetes. Congress:ASCO 2022, Search all connections
Abstract Evaluation of homologous recombination deficiency biomarkers in patients with ovarian cancer treated with PARP inhibitors. Congress:ASCO 2022, Search all connections
Abstract Treatment and outcome of patients with high-grade advanced ovarian cancer (AOC): Real-world data in Germany (QS Ovar of the AGO Study Group). Congress:ASCO 2022, Search all connections
Abstract Defining a prognostic risk score in ovarian cancer patients by integrated analysis of serum mesothelin, HE4, CA125 and surgical outcome. Congress:ASCO 2022, Search all connections
Abstract Real-world outcomes of niraparib treatment in patients with ovarian cancer: The first observational multicenter study in China. Congress:ASCO 2022, Search all connections
Abstract End-of-life care for patients with advanced ovarian cancer in the Netherlands: A retrospective registry-based analysis. Congress:ASCO 2022, Search all connections
Abstract Diagnosis of first relapse and its impact on quality of life in patients with advanced ovarian cancer (AGO-OVAR 19/II). Congress:ASCO 2022, Search all connections
Abstract Rates and results of germline genetic testing in patients with epithelial ovarian cancer at a tertiary care center. Congress:ASCO 2022, Search all connections
Abstract The tumor immune microenvironment correlates with neoadjuvant chemotherapy response in high-grade serous ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Methylated DNA markers discriminate ovarian cancer from benign tissue in BRCA carriers. Congress:ASCO 2022, Search all connections
Abstract Liquid-biopsy-derived glycoproteomic profiling as a novel means for noninvasive diagnosis of ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Characteristics of germline DNA damage response gene mutations in ovarian cancer in Southwest China. Congress:ASCO 2022, Search all connections
Abstract Multi-omics analysis reveals spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract A deep learning solution for detection of homologous recombination deficiency in ovarian cancer using low pass whole-genome sequencing: Evaluation of the analytical performance. Congress:ASCO 2022, Search all connections
Abstract Distribution of homologous recombination deficiency (HRD) and BRCA mutations (m) detected by HRD-One test among Brazilian patients (pts) with newly diagnosed advanced epithelial ovarian, fallopian tube, or peritoneal cancer. Congress:ASCO 2022, Search all connections
Abstract Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis. Congress:ASCO 2022, Search all connections
Abstract Patterns and prevalence of pathogenic germline mutations using multi-gene panel testing in patients with ovarian cancer: The Jordanian Exploratory Cancer Genetics (Jo-ECAG) Ovarian Study. Congress:ASCO 2022, Search all connections
Abstract Changes in focal adhesion protein Talin-1 expression during malignant transformation leading to ovarian high-grade serous carcinoma. Congress:ASCO 2022, Search all connections
Abstract Associations between genomic instability score (GIS), molecular characterization, and clinical outcomes in high grade serous ovarian cancers (HGSOC). Congress:ASCO 2022, Search all connections
Abstract Efficacy and safety of apatinib in the treatment of advanced platinum-resistant recurrent epithelial ovarian cancer: A retrospective study. Congress:ASCO 2022, Search all connections
Abstract Early mortality in epithelial ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Analytical evaluation of a commercial in-house homologous recombination deficiency (HRD) assay for patients with epithelial ovarian cancers and its concordance with a reference standard. Congress:ASCO 2022, Search all connections
Abstract Therapeutic implications of mutations in high grade serous ovarian carcinoma when evaluated by race. Congress:ASCO 2022, Search all connections
Abstract The correlation of homologous recombination deficiency status with and Olaparib efficacy in Chinese ovarian cancer patients. Congress:ASCO 2022, Search all connections
Abstract Exploring the mechanism of PARPi resistance in ovarian cancer by integrated analyze of pre- and post-progression samples in 5 patients. Congress:ASCO 2022, Search all connections
Abstract Cost-effectiveness of Olaparib plus Bevacizumab versus Bevacizumab in the maintenance of patients with HRD+ advanced ovarian cancer after response to first-line platinum-based chemotherapy in Spain. Congress:ASCO 2022, Search all connections
Abstract Evaluating the use of machine learning use in ovarian cancer: A systematic review. Congress:ASCO 2022, Search all connections
Abstract Prognostic factors of stage I endometrioid or clear cell or mucinous ovarian cancer: Analysis based on surveillance, epidemiology, and end result program, 2000-2016. Congress:ASCO 2022, Search all connections
Abstract Evaluating the utility of ctDNA in detecting residual cancer and predicting recurrence in patients with serous ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Cancer stem cell assay for identification of effective treatments for platinum-resistant recurrent ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Platinum vs non-platinum chemotherapy for platinum-resistant ovarian cancer: A meta-analysis. Congress:ASCO 2022, Search all connections
Abstract POSTCare-O: A survivorship care transition for women with ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Exploratory hrd and PD-L1 analysis of l-MOCA study: Olaparib maintenance monotherapy in Asian patients with platinum-sensitive relapsed ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Interim analysis from a phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: APGOT-ov4/ OPEB-01. Congress:ASCO 2022, Search all connections
Abstract Assessing homologous recombination deficiency (HRD) in ovarian cancer: Optimizing concordance of the regulatory-approved companion diagnostic and a next-generation sequencing (NGS) assay kit. Congress:ASCO 2022, Search all connections
Abstract Brain metastases in ovarian cancer: Association of outcomes with timing of diagnosis. Congress:ASCO 2022, Search all connections
Abstract ODALIE Study, a retrospective analysis of a real-life cohort of patients with de novo advanced high grade epithelial ovarian cancer treated with a first-line platinum- and taxane-based chemotherapy combined with bevacizumab. Congress:ASCO 2022, Search all connections
Abstract The influence of carrying BRCA pathogenic mutations in ovarian cancer and its platinum-sensitivity: 5-year experience of a tertiary center. Congress:ASCO 2022, Search all connections
Abstract Burden of cremophor-related paclitaxel therapy on patients with ovarian cancer: A patient focused study from the United Kingdom, Germany, and Spain. Congress:ASCO 2022, Search all connections
Abstract Genomic characteristics of homologous recombination deficiency in ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Exploring the value of intraoperative frozen section in the diagnosis and treatment of patients with early-stage ovarian cancer: A retrospective analysis of 421 patients. Congress:ASCO 2022, Search all connections
Abstract Impact of tumor percentage on the assessment of homologous recombination deficiency score using a NGS 523 gene panel and a cytogenetic software in the evaluation of epithelial ovarian tumors. Congress:ASCO 2022, Search all connections
Abstract Evaluation of PD-1/PD-L1 and CTLA-4 immune checkpoints and angiogenic activity in ovarian cancer after oncotherad immunotherapy associated to erythropoietin. Congress:ASCO 2022, Search all connections
Abstract Data independent acquisition mass spectrometry in relation to potential diagnostic and prognostic biomarkers for high-grade serous ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Detection of early-stage ovarian cancer using a liquid biopsy test based on extracellular vesicle proteins. Congress:ASCO 2022, Search all connections
Abstract Identifying DNA methylation signatures in high-grade serous ovarian cancer: Results vary by control tissue type. Congress:ASCO 2022, Search all connections
Abstract Mechanisms of thrombosis pathogenesis and prevention vary in patients with ovarian and endometrial cancers. Congress:ASCO 2022, Search all connections
Abstract Chemotherapy and radiofrequency hyperthermia in advanced ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract On a possible mechanism of platinum resistance development in patients with advanced ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Effects of five prescriptions in Synopsis of Golden Chamber on the malignant phenotype and expression of CA125, CEA, HE4 proteins in human ovarian cancer cells. Congress:ASCO 2022, Search all connections
Abstract Anti-cancer effects of high-dose selenium via lipid peroxidation in ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract BRCA1/2 genes mutations frequency in patients with various histological types of ovarian cancer (data for South of Russia). Congress:ASCO 2022, Search all connections
Abstract PACSIN3 is a novel biomarker for platinum resistance BRCA mutated platinum resistance epithelial ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Anlotinib plus letrozole in patients with platinum-resistant recurrent ovarian cancer: A prospective, single-arm, open-label, phase II study. Congress:ASCO 2022, Search all connections
Abstract Connective tissue growth factor expression maintains the epithelial phenotype of ovarian cancer in early epithelial to mesenchymal transition. Congress:ASCO 2022, Search all connections
Abstract Long-term survival in newly-diagnosed ovarian cancer patients. Congress:ASCO 2022, Search all connections
Abstract Anlotinib suppresses growth and metastasis through MAPK signaling pathway in cisplatin-resistant ovarian cancer cells. Congress:ASCO 2022, Search all connections
Abstract Clinicopathological analysis of 285 cases of elderly patients with epithelial ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract BRCA variants and the risk of adverse reactions in patients with ovarian cancer: A single-center real-world study. Congress:ASCO 2022, Search all connections
Abstract Utilization of immortalized B cells to identify SDCBP as a novel therapeutic target in ovarian carcinoma. Congress:ASCO 2022, Search all connections
Abstract Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial. Congress:ASCO 2022, Search all connections
Abstract NRG-CC008: A nonrandomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers [SOROCk]. Congress:ASCO 2022, Search all connections
Abstract Genetic counselling and testing for breast and ovarian cancer in Asia: A multinational survey of unmet needs. Congress:ASCO 2022, Search all connections
Abstract Retrospective analysis of non-BRCA gene pathogenicity variation in Chinese patients with ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Trends in and determinants of germline BRCA1/2 testing in patients with breast and ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract STRO-002-GM2: A phase 1, open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-002, an anti-folate receptor alpha (FolRα) antibody-drug conjugate (ADC), in combination with bevacizumab in patients with advanced epithelial ovarian cancer (EOC, including fallopian tube or primary peritoneal cancers). Congress:ASCO 2022, Search all connections
Abstract PERCEPTION: Phase II investigational study of pembrolizumab combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer— A NOGGO trial. Congress:ASCO 2022, Search all connections
Abstract FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double-blind, placebo-controlled, global, multinational study. Congress:ASCO 2022, Search all connections
Abstract ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus investigator’s choice in advanced, platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer. Congress:ASCO 2022, Search all connections
Abstract ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC). Congress:ASCO 2022, Search all connections
Abstract ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract GRN300–001: Phase 1/1B evaluation of the safety, pharmacokinetics, and efficacy of GRN-300, a salt-inducible kinase inhibitor, alone and in combination with paclitaxel, in recurrent ovarian, primary peritoneal, and fallopian tube cancers. Congress:ASCO 2022, Search all connections
Abstract A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα)-high recurrent ovarian cancer eligible for platinum-based chemotherapy. Congress:ASCO 2022, Search all connections
Abstract TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab versus best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum. Congress:ASCO 2022, Search all connections
Abstract AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC). Congress:ASCO 2022,ASCO 2019, Search all connections
Abstract SCOUT-1: Prospective non-interventional study in patients with BRCA/HRD-tested ovarian cancer (OC) eligible for first-line (1L) platinum-based chemotherapy (NOGGO ov54). Congress:ASCO 2022, Search all connections
Abstract A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial. Congress:ASCO 2022, Search all connections
Abstract Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018). Congress:ASCO 2022, Search all connections
Abstract ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Congress:ASCO 2022, Search all connections
Abstract Stage 1 results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas (NCT03355976). Congress:ASCO 2022, Search all connections
Abstract Dysfunctional CD8+ T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC). Congress:ASCO 2022, Search all connections
Abstract Bevacizumab combined with platinum-based chemotherapy in patients with primary or relapsed ovarian cancer: Meta-analysis and literature review. Congress:ASCO 2022, Search all connections
Abstract Trends in frontline PARP inhibitor maintenance in advanced epithelial ovarian cancer across the United States. Congress:ASCO 2022, Search all connections
Abstract PemBOv trial: Pembrolizumab plus bevacizumab with or without pegylated liposomal doxorubicin-based chemotherapy in patients with platinum-resistant ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Pharmacokinetic and pharmacodynamic analysis of adavosertib in advanced ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract CeNtuRIOn: Rucaparib (R) with nivolumab (N) and ipilimumab (I) in patients (pts) with relapsed ovarian cancer (ROC)—Results of an initial safety cohort. Congress:ASCO 2022, Search all connections
Abstract A multicenter phase II randomized trial of durvalumab (D) versus physician’s choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3). Congress:ASCO 2022, Search all connections
Abstract Integrated safety summary of single-agent mirvetuximab soravtansine in patients with folate receptor α (FRα)-positive recurrent ovarian cancer: Phase 1 and 3 clinical trials. Congress:ASCO 2022, Search all connections
Abstract MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC). Congress:ASCO 2022, Search all connections
Abstract Breast cancer incidence in patients with BRCA-related advanced ovarian cancer receiving olaparib-based maintenance therapy: A pooled analysis from phase III clinical trials. Congress:ASCO 2022, Search all connections
Abstract Quality of life in patients with advanced high-grade ovarian cancer (HGOC) receiving maintenance therapies after first-line (1L) chemotherapy in the randomized phase III PAOLA-1/ENGOT-ov25 trial (NCT02477644). Congress:ASCO 2022, Search all connections
Abstract A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Time without symptoms or toxicity (TWiST) in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib or placebo plus bevacizumab: Analysis of PAOLA-1/ENGOT-ov25 phase III trial. Congress:ASCO 2022, Search all connections
Abstract Potential indicators in circulating cell-free DNA for monitoring PARP inhibitor resistance in high-grade serous ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer. Congress:ASCO 2022, Search all connections
Abstract OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis—An exploratory joint analysis of the BRCA and non-BRCA cohorts. Congress:ASCO 2022, Search all connections
Abstract Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Final complete resection and pathological response rates. Congress:ASCO 2022, Search all connections
Abstract Prospective identification of prognostic factors for patients with early failure of advanced ovarian cancer who undergo primary cytoreductive surgery followed by chemotherapy: The AGO-OVAR 19/FRAGILE study (NCT02828618). Congress:ASCO 2022, Search all connections
Abstract Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Prior authorizations for PARP inhibitors in ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Immune tumor microenvironnement (iTME) post-neoadjuvant chemotherapy, beyond PD-L1: Novel immune targets in ovarian cancer, data from the CHIVA trial, a GINECO/GINEGEPS study. Congress:ASCO 2022, Search all connections
Abstract Identification of patients with ovarian cancer who are experiencing the highest benefit from bevacizumab in first-line setting based on their tumor intrinsic chemosensitivity (KELIM): GOG-0218 validation study. Congress:ASCO 2022, Search all connections
Abstract The effect of advances in epithelial ovarian cancer treatment on population mortality. Congress:ASCO 2022, Search all connections
Abstract Real-world use, tolerability, and dose modifications of PARP inhibitors in ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Safety and efficacy of mitoxantrone hydrochloride liposome in patients with platinum-refractory or platinum-resistant ovarian cancer: A prospective, multicenter, open-label, single-arm, phase Ib clinical trial. Congress:ASCO 2022, Search all connections
Abstract Copy number features as a novel biomarker of homologous recombination (HR) status in high-grade serous ovarian cancer (HGSOC). Congress:ASCO 2022, Search all connections
Abstract Clinical implications of tumor-based next-generation sequencing in ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Validation of the integrated prediction model algorithm for outcome of cytoreduction in advanced ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Efficacy and safety of rucaparib maintenance treatment in patients from ARIEL3 with platinum-sensitive, recurrent ovarian carcinoma not associated with homologous recombination deficiency. Congress:ASCO 2022, Search all connections
Abstract Efficacy and safety of pembrolizumab in combination with anlotinib in the treatment of refractory or recurrent high-grade serous ovarian cancer: A phase 2 nonrandomized clinical trial. Congress:ASCO 2022, Search all connections
Abstract Extracellular vesicle-based biomarker assay for the detection of early-stage ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Efficacy and toxicity of carboplatin and gemcitabine dosed on day 1/day 8 versus day 1 alone for platinum-sensitive recurrent epithelial ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract A phase 1 trial of the PARP inhibitor fuzuloparib in combination with the anti-angiogenic apatinib in recurrent ovarian or triple-negative breast cancer. Congress:ASCO 2022, Search all connections
Abstract Cytoreductive surgery plus HIPEC for advanced epithelial ovarian cancer: Analysis from a multicentric national Indian HIPEC registry of 1,470 patients—An ISPSM Collaborative study. Congress:ASCO 2022, Search all connections
Abstract Pressurized intraperitoneal aerosol chemotherapy (PIPAC) versus intravenous chemotherapy in unresectable peritoneal metastases secondary to platinum-resistant ovarian cancer: Interim analysis of Indian randomized control trial. Congress:ASCO 2022, Search all connections
Abstract Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC). Congress:ASCO 2022, Search all connections
Abstract Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results. Congress:ASCO 2022, Search all connections
Abstract A phase 3, single arm, open-label study evaluating ovarian suppression following 3-month leuprolide acetate for injectable suspension in combination with endocrine therapy in premenopausal subjects with HR+, HER2-negative breast cancer (OVELIA). Congress:ASCO 2022, Search all connections
Abstract Estradiol (E2) levels in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC) on ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa). Congress:ASCO 2022, Search all connections
Abstract A multicenter study of clinical impact of variant of uncertain significance reclassification in breast, ovarian, and colorectal cancer susceptibility genes. Congress:ASCO 2022, Search all connections
Abstract A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150. Congress:ASCO 2022, Search all connections
Abstract Real-world effectiveness of first-line maintenance olaparib in women with BRCA-mutated advanced ovarian cancer: U.S. retrospective cohort study. Congress:ASCO 2022, Search all connections
Abstract Basket study of oral progesterone antagonist onapristone extended release (ONA-XR) in progesterone receptor positive (PR+) recurrent granulosa cell (GCT), low-grade serous ovarian (LGSOC), or endometrioid endometrial cancer (EEC). Congress:ASCO 2022, Search all connections
Abstract Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study. Congress:ASCO 2022, Search all connections
Abstract Role of cytoreductive surgery for the second ovarian cancer relapse in patients previously treated with chemotherapy alone at first relapse: A subanalysis of the DESKTOP III trial. Congress:ASCO 2022, Search all connections
Abstract Adavosertib in combination with carboplatin in advanced TP53-mutated platinum-resistant ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract IGNITE: A phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification. Congress:ASCO 2022, Search all connections
Abstract Safety and efficacy of MORAb-202 in patients (pts) with platinum-resistant ovarian cancer (PROC): Results from the expansion part of a phase 1 trial. Congress:ASCO 2022, Search all connections
Abstract Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study. Congress:ASCO 2022, Search all connections
Abstract Constitutional BRCA1 methylation and risk of incident triple-negative breast cancer and high-grade serous ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Pembrolizumab, maveropepimut-S, and low-dose cyclophosphamide in advanced epithelial ovarian cancer: Results from phase 1 and expansion cohort of PESCO trial. Congress:ASCO 2022, Search all connections
Abstract ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23). Congress:ASCO 2022, Search all connections
Abstract A phase I/II study of ruxolitinib with frontline neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer. Congress:ASCO 2022, Search all connections
Abstract Bevacizumab in first-line chemotherapy to improve the survival outcome for advanced ovarian clear cell carcinoma: A multicenter, retrospective analysis. Congress:ASCO 2022, Search all connections
Abstract Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer. Congress:ASCO 2022, Search all connections
Abstract Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC). Congress:ASCO 2022, Search all connections
Abstract Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8-year follow-up of the randomized ASTRRA trial. Congress:ASCO 2022, Search all connections
Abstract Sexuality as a prognostic factor: Results of an individual participant data NOGGO-meta-analysis of 1,041 recurrent ovarian cancer patients before starting chemotherapy. Organization:Charite-Universitäts...,Charité - University...,North-Eastern German...,Drug:Treosulfan,Hector,Target:Hector,DNA,Congress:ASCO 2023, Search all connections
Abstract Pilot randomized trial of a telehealth intervention for women with advanced ovarian cancer and PARP inhibitor-related fatigue. Organization:Dana-Farber Cancer I...,University of Colora...,Harvard Medical Scho...,Drug:Poly(ADP-ribose) pol...,PARPi, Search all connections
Abstract Relative and functioning sleep disturbance and fatigue: Impact on patients with ovarian cancer. Organization:Cancer Support Commu...,Merck & Co., Inc.,Drug:Merck Sharp & Dohme ...,AstraZeneca UK Ltd.,Target:sleep disturbance,fatigue,AstraZeneca UK Ltd.,Congress:ASCO 2023, Search all connections
Abstract The effect of formal education on ovarian cancer, clinical trial access, and clinical trial awareness among Black and Latino US women. Organization:MiOra,Congress:ASCO 2023, Search all connections
Abstract Evaluating root causes contributing to real-world disparities in ovarian cancer care: Insights from an implementation science initiative utilizing tethered patient-provider surveys and chart reviews. Organization:PRIME Education LLC,Stephenson Cancer Ce...,Drug:AstraZeneca,GlaxoSmithKline,Merck & Co. Inc.,Target:BRCA1,BRCA testing,PARP inhibitors, Search all connections
Abstract How to close the care gap: Factors hindering the use of BRCA mutation profiling of patients with breast cancer and ovarian cancer in a real world setting. Organization:MVR Cancer Centre & ...,Drug:PARP inhibitors,Target:PARP2,PARP1,Congress:ASCO 2023, Search all connections
Abstract Enrollment representation of age, race, and ethnicity in ovarian cancer registrational clinical trials (2010-2020): An evaluation by the U.S. Food and Drug Administration. Organization:Oncology Center of E...,Office of the Commis...,U.S. Food and Drug A...,Drug:epithelial ovarian, Search all connections
Abstract Assessing the translation capabilities of NCI-designated cancer websites with a focus on lung, breast, prostate and ovarian cancers. Organization:Lenox Hill Hospital,Congress:ASCO 2023, Search all connections
Abstract Genetic evaluations and testing rates for hereditary breast and ovarian cancer syndrome in a community oncology setting. Organization:Texas Oncology,Texas Oncology Centr...,Congress:ASCO 2023, Search all connections
Abstract Serial monitoring of ovarian cancer risk in women with adnexal mass. Organization:Aspira Women's Healt...,Bee Cave, TX,Austin, TX,Drug:MIA3G,Target:serum biomarkers,Congress:ASCO 2023, Search all connections
Abstract Multivariate index assay (MIA3G) to reduce preventive surgery for ovarian cancer. Organization:Aspira Women's Healt...,Axia Women's Health,Drug:CA125,HE4,BM2, Search all connections
Abstract Multivariate index assay MIA3G vs other assessment tools for the ovarian cancer risk assessment of indeterminate masses. Organization:Aspira Women's Healt...,Austin Health,Aspira Women's Healt...,Drug:MIA3G,ROMA,Target:B2M,TFRC, Search all connections
Abstract OncoTherad immunotherapy plus platelet rich plasma as potential therapeutic strategy for ovarian cancer: The role of toll-like receptors 2 and 4 signaling pathways. Organization:Laboratory of Urogen...,Institute of Biology,University of Campin...,Drug:OncoTherad,Platelet Rich Plasma,PRP,Target:TLR2,TLR4, Search all connections
Abstract Does age matter? An ovarian cancer cohort from a single, urban, academic institution. Organization:Icahn School of Medi...,Icahn School of Medi...,Icahn School of Medi...,Congress:ASCO 2023, Search all connections
Abstract GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of ovarian cancer. Organization:AOA Dx Inc,Lady Davis Institute...,McGill University He...,Drug:GD2-SADA, Search all connections
Abstract Clinical predictors of survival in advanced epithelial ovarian cancer: Can we foresee the long-term survivors and develop a personalized treatment approach? Organization:Tel Aviv Sourasky Me...,Division of Oncology...,Sourasky Medical Cen...,Drug:Tiragolumab,carboplatin,Target:beta-tubulin, Search all connections
Abstract Circulating tumor DNA-based molecular residual disease detection for the monitoring of high-grade serous ovarian cancer. Organization:Xinhua Hospital Affi...,Shanghai OrigiMed Co...,Drug:platinum-based chemo...,Target:ATM,FANCL,BRCA1,Congress:ASCO 2023, Search all connections
Abstract Role of BRCA1 promotor methylation (BRCA1meth) in homologous recombination deficiency (HRD) in high-grade epithelial ovarian cancer. Organization:Innsbruck Medical Un...,Department of Obstet...,Innsbruck, Austria,Drug:platinum-based chemo...,Target:BRCA1,Congress:ASCO 2023, Search all connections
Abstract Overall survival in treated ovarian cancer patients in Argentina: OCEANIA study. Organization:GSK Research and Dev...,Hospital Italiano de...,Drug:antineoplastics,platinum-based treat...,Target:Platinum-based treat...,antineoplastics,Congress:ASCO 2023, Search all connections
Abstract PARPi monotherapy as first-line maintenance following chemotherapy + bevacizumab in advanced ovarian cancer. Organization:South Carolina Oncol...,Precision Q,Integra Connect,Drug:bevacizumab,olaparib,niraparib, Search all connections
Abstract Prognostic and predictive significance of CA-125 elimination rate constant K (KELIM) in ovarian cancer patients treated with neoadjuvant chemotherapy in a real-world setting. Organization:Haematology- Oncolog...,Department of Clinic...,Alexandra Hospital -..., Search all connections
Abstract Real-world outcomes of first-line maintenance with niraparib or bevacizumab in advanced ovarian cancer. Organization:Precision Q,Integra Connect,GSK Research and Dev...,Drug:niraparib,bevacizumab,Target:Poly(ADP-ribose) pol...,VEGF and c-MET pathw..., Search all connections
Abstract Factors associated with platinum sensitivity (PST) and related outcomes in patients with ovarian cancer (OC) in a US community oncology setting: Looking beyond. Organization:David Geffen School ...,Arizona Center for C...,Ontada,Drug:platinum-based chemo...,bevacizumab,Target:vascular endothelial...,DNA, Search all connections
Abstract Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor (PARP) in patients with newly diagnosed ovarian cancer: A systematic review and meta-analysis. Organization:Centro de Oncologia ...,Princess Margaret Ho...,Catholic University ..., Search all connections
Abstract Comprehensive HRD testing in epithelial ovarian cancer: A further step toward personalized therapy decisions. Organization:Innsbruck Medical Un...,Department of Obstet...,Innsbruck, Austria, Search all connections
Abstract Levels of ANGPTL3 and characterization of other circulating cholesterol-related factors in high-grade serous ovarian cancers. Organization:CHU de Québec-Univer...,CHU de Québec - Univ...,CHU de Québec-Univer...,Drug:ANGPTL3, Search all connections
Abstract Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage ovarian cancer: A prospective multicentre study (SELLY). Organization:Fondazione Policlini...,Presidio Ospedaliero...,Fondazione Giovanni ..., Search all connections
Abstract Resistance mechanism and microenvironment changes after PARPi treatment: Paired analysis of ovarian cancer samples pre and post treatment. Organization:Department of Obstet...,Key Laboratory of Bi...,Department of Pathol...,Drug:PARP inhibitors,Target:PARP,Congress:ASCO 2023, Search all connections
Abstract Cost-effective analysis of rotational intraperitoneal aerosol chemotherapy (RIPAC) in patients with platinum-resistant ovarian cancer. Organization:Seoul National Unive...,Seoul National Unive...,Drug:pegylated liposomal ...,FF-10832,topotecan, Search all connections
Abstract A DMBA-induced ovarian cancer model: Could it be clinically useful to test OncoTherad and erythropoietin as anticancer approaches? Organization:Laboratory of Urogen...,Drug:OncoTherad,Erythropoetin,Target:FOXP3,CD3,ARID1A, Search all connections
Abstract Targeting regeneration capacity of stem cells to improve surgical wound healing outcomes in ovarian cancer patients. Organization:MD Anderson Cancer C...,Rowan University Sch...,Cooper University Ho...,Drug:I3C,EGCG,carboplatin,Target:RANTES,I-309, Search all connections
Abstract Effect of testing for BRCA1/2 on outcomes in patients with ovarian cancer treated with PARPi in 1st line maintenance (1LM). Organization:Florida Cancer Speci...,Integra Connect Prec...,Illumina, Inc.,Drug:bevacizumab,niraparib,olaparib, Search all connections
Abstract Prognostic value of insulin-like growth factor receptor 1 (IGF1R) expression in high-grade serous ovarian cancer (HGSOC) treated with first line platinum derivative based chemotherapy. Organization:Military Institute o...,Oncology Department,Medical University o...,Drug:platinum derivative,Target:IGF1RA,Congress:ASCO 2023, Search all connections
Abstract Clinical features of long-term survivors with advanced high-grade serous ovarian cancer. Organization:Medical Oncology Gro...,Catalan Institute of...,Medical School Unive..., Search all connections
Abstract The impact of homologous recombination deficiency on first-line adjuvant chemotherapy and first-line PARPi maintenance therapy in Chinese patients with epithelial ovarian cancer. Organization:Peking Union Medical...,Department of Obstet...,West China Second Un..., Search all connections
Abstract The impact of lymphadenectomy on survival outcomes of ovarian clear cell carcinoma: A systematic review and meta-analysis. Organization:Qilu Hospital of Sha...,Jinan, China,Congress:ASCO 2023, Search all connections
Abstract Real world study on the effect of PARPi as maintenance therapy after first-line and second-line chemotherapy on platinum sensitivity in patients with recurrent high-grade serous epithelial ovarian cancer. Organization:Zhejiang Cancer Hosp...,Zhejiang Cancer Hosp...,Drug:PARPi,Target:PARP,Congress:ASCO 2023, Search all connections
Abstract Genomic and transcriptomic characterization of ovarian cancer under neoadjuvant and adjuvant chemotherapy. Organization:Peking Union Medical...,Precision Scientific...,University of Texas ...,Drug:platinum-based chemo...,Target:homologous recombina...,MSI (microsatellite ...,CCNE1,Congress:ASCO 2023, Search all connections
Abstract A web-based prediction model for overall survival of elderly patients with epithelial ovarian cancer: A population-based study. Organization:Qilu Hospital of Sha...,Jinan, China,Drug:Cisplatin,Target:chemotherapy,Congress:ASCO 2023, Search all connections
Abstract Prognostic risk stratification of low-grade serous ovarian cancer: Model development and validation based on machine learning algorithm. Organization:Qilu Hospital of Sha...,Jinan, China,Congress:ASCO 2023, Search all connections
Abstract Quality of life (QoL) in patients with recurrent ovarian clear cell carcinoma (rOCCC) receiving durvalumab (D) versus physician’s choice chemotherapy (PCC) in the randomized phase II MOCCA/APGOT-OV2/GCGS-OV3 trial. Organization:National University ...,Saw Swee Hock School...,Samsung Medical Cent..., Search all connections
Abstract Genetic counseling and testing for epithelial ovarian cancer in a diverse patient population. Organization:NewYork-Presbyterian...,Brooklyn ImmunoThera...,SUNY Downstate Medic...,Congress:ASCO 2023, Search all connections
Abstract Comparison of BRCA genetic testing and subsequent treatment with PARP inhibitors (PARPi) for ederly vs non-elderly women with non-mucinous epithelial ovarian cancer (EOC): A large prospective cohort study from the Australian National Gynaecology Oncology Registry (NGOR). Organization:Monash University Sc...,Peter MacCallum Canc...,The Royal Women's Ho...,Drug:PARPi,Target:BRCA1,BRCA2, Search all connections
Abstract The landscape of BRCA1 and BRCA2 alterations in Chinese ovarian cancer patients. Organization:Department of Gyneco...,Department of Gyneco...,Yinfeng Gene Technol...,Drug:BRCA1,BRCA2,Target:BRCA1,BRCA2, Search all connections
Abstract Proteomic profiling of peritoneal fluid-derived exosomes as a tool for the identification of prognostic markers in advanced ovarian carcinomas. Organization:Clara Campal Compreh...,Clara Campal Cancer ...,HM Sanchinarro Centr..., Search all connections
Abstract Is laparoscopic approach feasible in early-stage ovarian cancer? A retrospective study in single tertiary center. Organization:Chang Gung Memorial ...,Congress:ASCO 2023, Search all connections
Abstract Can epigenetic treatments efficiently revoke the ability of 3D ovarian cancer cells to proliferate, migrate, and invade? Organization:Cooper University Ho...,MD Anderson Cancer C...,Drug:EGCG,Indole-3-carbinol,panobinostat,Target:DNA methyltransferas..., Search all connections
Abstract Impact of postoperative residual disease in patients with primary epithelial ovarian cancer in the era of maintenance therapies with targeted agents: A systematic review and meta-analysis. Organization:National Cancer Cent...,Seoul National Unive...,National Cancer Cent..., Search all connections
Abstract The peripheral TCR repertoire diversity indexes can be used as an independent indicator for long term survival rate of ovarian cancer patients. Organization:Department of Obstet...,Chengdu, Sichuan, Ch...,Department of Health...,Congress:ASCO 2023, Search all connections
Abstract Clinical safety and efficacy observation of ex vivo-expanded peripheral blood-derived allogeneic NK cells in the treatment of refractory or recurrent ovarian cancer. Organization:The First Affiliated...,Division of Life Sci...,Institute of Immunol...,Drug:allogeneic NK cells,Target:ovarian cancer cells,Congress:ASCO 2023, Search all connections
Abstract A combination of niraparib plus anlotinib in patients with platinum-resistant ovarian clear cell carcinoma: Results of a single-arm phase II study (CC-ANNIE study). Clinical trial:2021-KY-016,Organization:Sun Yat-Sen Memorial...,Guangzhou JOYO Pharm...,China National Biote..., Search all connections
Abstract A real-world study of US patients with metastatic ovarian, fallopian tube, and peritoneal cancer (mOFPC) using integrated electronic health records (EHR) and claims datasets. Organization:ConcertAI,Labcorp Oncology, Du...,Labcorp Drug Develop...,Drug:Cisplatin,carboplatin,Tiragolumab, Search all connections
Abstract Genetic counseling referral frequency and attrition for newly diagnosed epithelial ovarian cancer at Grady Memorial Hospital from 2012-2022. Organization:Emory University Hos...,Winship Cancer Cente...,Emory University Sch...,Drug:PARPi,Target:BRCA1,BRCA2,Congress:ASCO 2023, Search all connections
Abstract Effect of multi-targeting bacterial gene therapy on tumour regression and survival in mouse models of ovarian and intraperitoneal cancer. Organization:Aurealis Therapeutic...,Kuopio University Ho...,Finland,Drug:AUP-55,Target:interleukin 12 (IL-1...,interferon alpha (IF..., Search all connections
Abstract Using chemotherapy response by KELIM score to predict response to first line maintenance PARP inhibitor therapy in non-BRCA mutant/homologous recombination deficiency (HRD) unknown high grade serous ovarian cancer (HGSOC). Organization:BC Cancer-Vancouver ...,University of Britis...,Drug:niraparib,Target:PARP,Congress:ASCO 2023, Search all connections
Abstract Clinical remission rates in patients with epithelial ovarian cancer in the pandemic versus the pre-pandemic period. Organization:Adventist Health Whi...,Kaiser Permanente Oa...,Kaiser Permanente So...,Drug:COVID-19 vaccine,oval cancer, Search all connections
Abstract Circulating tumor DNA–based detection of molecular residual disease as a biomarker for recurrence monitoring predict disease recurrence in patients with ovarian cancer. Organization:Ruijin Hospital, Sha...,Shanghai Jiaotong Un...,Shanghai Zhengu Biol...,Congress:ASCO 2023, Search all connections
Abstract Spatial profiling of ovarian clear cell carcinoma (OCCC) and identification of immune-hot features. Organization:National Taiwan Univ...,National Taiwan Univ...,Cancer Science Insti...,Congress:ASCO 2023, Search all connections
Abstract Molecular profile of SWI/SNF complex in Chinese patients with ovarian cancer. Organization:Nanjing Simcere Medi...,Jiangsu Simcere Diag...,Drug:ARID1A,ARID1B,SMARCA4, Search all connections
Abstract Effects of the baseline prognostic factors on efficacy of the p62/SQSTM1-encoding plasmid combined with gemcitabine in patients with recurrent platinum-resistant ovarian cancer. Organization:CureLab Oncology, In...,N.N. Alexandrov Nati...,Minsk City Clinical ...,Drug:FF-10832,p62/SQTM1-encoding p...,Target:Gemcitabine,p62/SQTM1, Search all connections
Abstract Comparison of bevacizumab plus doublet chemotherapy regimens in patients with metastatic or recurrent ovarian cancer. Organization:Istanbul University ...,Basaksehir Cam and S...,Drug:bevacizumab,FF-10832,carboplatin,Target:Gemcitabine, Search all connections
Abstract Diagnostic model of low-grade serous ovarian cancer and borderline serous ovarian tumor: Model development and validation based on radiomics. Organization:Qilu Hospital of Sha...,Shandong University ...,Congress:ASCO 2023, Search all connections
Abstract Homologous recombination deficiency (HRD) status and response to platinum-based chemotherapy and PARP inhibitors in Chinese patients with ovarian cancer. Organization:Cancer Hospital Chin...,Drug:platinum-based chemo...,PARP inhibitors,Target:homologous recombina...,PARP,Congress:ASCO 2023, Search all connections
Abstract A phase I dose-finding trial of hyperthermic intraperitoneal docetaxel combined with cisplatin in patients with advanced-stage ovarian cancer. Organization:Department of Gyneco...,Department of Gyneco...,Department of Gyneco...,Drug:docetaxel,Cisplatin,Target:docetaxel,RNA, Search all connections
Abstract Safety and survival in adult women with platinum sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study. Organization:Department of Medica...,Bayindir Sogutozu Ho...,Istanbul University ..., Search all connections
Abstract AXL pathway as a target to overcome resistance to PARP inhibitors in high-grade serous ovarian (HGSOC) and triple-negative breast cancer (TNBC) cell lines. Organization:Hospital Clinico Uni...,INCLIVA-Biomedical R...,CIBERONC - ISCIII, Search all connections
Abstract A cross-sectional study of 73,390 women without ovarian cancer and the effect of age and benign gynecological diseases on serum CA125 levels. Organization:The First Affiliated...,University of Scienc...,Provincial Hospital ...,Drug:CA125,Target:CA125,Congress:ASCO 2023, Search all connections
Abstract The combination of APR-246 and carboplatin in olaparib-resistant high grade serous ovarian cancer (HGSOC) and triple negative breast cancer (TNBC) cell lines. Organization:Department of Medica...,Hospital Clínico Uni...,Instituto de Investi..., Search all connections
Abstract Olaparib in HR-deficient (HRD), metastatic triple-negative breast cancer (TNBC) and relapsed ovarian cancer (ROC) without germline mutations in BRCA1 or BRCA2: Phase 2 EMBRACE trial. Organization:NHMRC Clinical Trial...,The University of Sy...,St George Hospital, Search all connections
Abstract Comprehensive multi-omic testing from a single laboratory to provide information in ovarian cancer. Organization:Myriad Genetics, Inc...,Myriad Genetic Labor...,Drug:BRCA,PMS2,MSIsensor,Target:BRCA2, Search all connections
Abstract Efficacy and safety study of a novel alpha-fetoprotein (AFP)-maytansine conjugate in an ovarian xenograft model. Organization:Alpha Cancer Technol...,Sunnybrook Research ...,Southern Research In...,Drug:AFP-maytansine conju...,staurosporine,thapsigargin,Target:AFP receptor, Search all connections
Abstract Therapeutic effect of a VSIG4-specific mAb EU103 in a preclinical model of patient-derived ascites of ovarian cancer. Organization:Eutilex Co., Ltd.,Samsung Medical Cent...,Sungkyunkwan Univers...,Drug:EU103,Target:VSIG4,Congress:ASCO 2023, Search all connections
Abstract The CROWN study (CaRdiac Outcomes With Near complete estrogen deprivation): A multicenter, prospective cohort study of cardiovascular outcomes in premenopausal women with hormone receptor positive breast cancer treated with ovarian suppression and an aromatase inhibitor. Organization:Wake Forest Universi...,Wake Forest School o...,Duke Cancer Institut...,Drug:aromatase inhibitor,ovarian function sup...,Target:Estrogen Receptors (..., Search all connections
Abstract Trends in the use of maintenance therapy in ovarian cancer. Organization:University of Texas ...,MD Anderson Cancer C...,Health Services Rese...,Drug:polyADP-ribose polym...,bevacizumab,olaparib,Target:PARP2, Search all connections
Abstract Use of germline testing in patients with prostate, pancreatic, or ovarian cancer in Washington (WA) state. Organization:Fred Hutchinson Canc...,University of Washin...,Congress:ASCO 2023, Search all connections
Abstract Healthcare utilization among individuals diagnosed with hereditary breast-ovarian cancer syndrome through a universal germline genetic testing program. Organization:City of Hope Compreh...,City of Hope Nationa...,City of Hope Nationa...,Drug:PARP inhibitors,Target:BRCA1,BRCA2,Congress:ASCO 2023, Search all connections
Abstract Cost-effectiveness analyses of population-based multi-gene testing for the prevention of breast and ovarian cancer in the United States. Organization:University of Texas ...,University of Texas ...,Drug:MRI,mammography,chemoprevention,Target:BRCA1, Search all connections
Abstract Real life use of biomarkers of homologous recombination deficiency (HRD) status beyond BRCA to predict the effectiveness of PARP inhibitors in ovarian cancer patients. Organization:Department of Surgic...,Drug:PARPi,Target:ATM,MUTYH,RAD51D, Search all connections
Abstract Hereditary breast and ovarian cancer syndrome: A misnomer? Organization:New York Medical Col...,Weill Cornell Medici...,Drug:ATM,BARD1,BRCA1/2, Search all connections
Abstract First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer. Clinical trial:R4018-ONC-1721,Organization:Stephenson Cancer Ce...,University of Oklaho...,Massachusetts Genera..., Search all connections
Abstract Uncovering mechanisms of response of pembrolizumab and lenvatinib for the treatment of platinum-resistant high grade serous ovarian cancer. Clinical trial:2020-1121,Organization:University of Texas ...,The University of Te...,University of Housto...,Drug:pembrolizumab,lenvatinib,Target:TGF-β, Search all connections
Abstract FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double blind, placebo controlled, global, multinational study. Clinical trial:QPT-ORE-005,Organization:National Cancer Cent...,CanariaBio, Inc, Lex...,CanariaBio, Inc, Sin..., Search all connections
Abstract Exactis-03: A phase I trial of the combination of olaparib and navitoclax in women with high grade serous ovarian cancer and triple negative breast cancer. Clinical trial:Exactis-03,Organization:Odette Cancer Centre,Sunnybrook Health Sc...,University of Montre..., Search all connections
Abstract GLORIOSA: A randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Clinical trial:IMGN853-0421,Organization:ImmunoGen,Drug:Mirvetuximab soravta...,bevacizumab,Target:tubulin,VEGF and c-MET pathw...,folate receptor-alph...,Congress:ASCO 2023, Search all connections
Abstract Oregovomab and non-platinum chemotherapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidates for platinum retreatment: A multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6). Clinical trial:4-2022-0430,Organization:Yonsei University Co...,Samsung Medical Cent...,Sungkyunkwan Univers...,Drug:PARP inhibitors, Search all connections
Abstract First trial of chemotherapy de-escalation in ovarian cancer (OC): A phase III randomized, open label study of niraparib maintenance after carboplatin and paclitaxel in patients with optimally debulked advanced (homologous recombination deficient) HRD high-grade ovarian cancer in first line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62). Clinical trial:NOGGO-ov53,Organization:Charite-Universitäts...,Stanford University ...,Institute for Biomet..., Search all connections
Abstract UP-NEXT (GOG-3049/ENGOT-Ov71-NSGO-CTU): A study of upitifamab rilsodotin (UpRi), a NaPi2b-directed antibody drug conjugate (ADC), in platinum-sensitive recurrent ovarian cancer. Clinical trial:XMT-1536-3,Organization:Stephenson Cancer Ce...,Sarah Cannon Researc...,Kliniken Essen-Mitte, Search all connections
Abstract TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum. Clinical trial:GINECO-OV244b,Organization:Gustave-Roussy Cance...,Institut Claudius Re...,IUCT-Oncopole Toulou..., Search all connections
Abstract UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade serous ovarian cancer (HGSOC). Clinical trial:XMT-1536-2A,Organization:Wexner Medical Cente...,Memorial Sloan Kette...,START Midwest, Grand..., Search all connections
Abstract ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68). Clinical trial:ALKS 4230-007,Organization:College of Medicine,...,Wexner Medical Cente...,Women's Cancer Care ..., Search all connections
Abstract The role of Chemotherapy Response Score (CRS) in the decision making process for advanced high grade serous ovarian cancer patients undergoing neoadjuvant chemotherapy. Organization:Fondazione Policlini...,Department of Obstet...,Catholic University ...,Drug:PARPis,Target:PARP,Congress:ASCO 2023, Search all connections
Abstract Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in BRCA wild-type patients with recurrent ovarian cancer. Clinical trial:213356,Organization:US Oncology Research...,GOG-Foundation,GSK Research and Dev...,Drug:niraparib,Target:BRCA1, Search all connections
Abstract Phase 1/1b study of PRGN-3005 autologous UltraCAR-T cells manufactured overnight for infusion next day to advanced stage platinum resistant ovarian cancer patients. Clinical trial:RG1004303,Organization:University of Washin...,Providence Cancer In...,Precigen, Inc.,Drug:PRGN-3005,Congress:ASCO 2023, Search all connections
Abstract Blinded-assessment of a solution to evaluate olaparib maintenance treatment efficacy in patients with ovarian cancer from the GINECO/ENGOT PAOLA-1 trial. Organization:Centre Léon Berard,UNIV Lyon-Université...,Genotypos M.S.A., Search all connections
Abstract Distinguishing primary mucinous ovarian tumors from metastases of non-gynecologic mucinous cancers: Can we leverage next-generation sequencing? Organization:Weill Cornell Medici...,Doha, Qatar,Qatar,Drug:CDKN2A/B, Search all connections
Abstract Immune features of ovarian tumors with a good response to neo-adjuvant chemotherapy in combination with an anti-PD-L1 alone or with an anti-CTLA4: Data from the randomized IneOV trial (a GINECO study). Clinical trial:GINECO-OV127b,Organization:Gustave-Roussy Cance...,GINECO-Centre Jean P...,Gustave Roussy Cance..., Search all connections
Abstract Triplet maintenance (olaparib, pembrolizumab, and bevacizumab) in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: A multi-center, single-arm phase II study (OPEB-01). Organization:Biomedical Statistic...,Department of Biomed...,Samsung Medical Cent...,Drug:olaparib,bevacizumab,pembrolizumab, Search all connections
Abstract Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States. Organization:Massachusetts Genera...,Meigs Division of Gy...,Vincent Department o...,Drug:neoadjuvant chemothe...,Congress:ASCO 2023, Search all connections
Abstract Effectiveness of PARP inhibitor maintenance therapy (mPARPi) in advanced ovarian cancer (OC) by BRCA1/2 and HRD signature in real-world practice. Organization:Stephenson Cancer Ce...,Sarah Cannon Researc...,Foundation Medicine,...,Drug:mPARPi, Search all connections
Abstract Exploring the significance of PARP inhibitor therapy after first-line chemotherapy in patients with homologous recombination proficient ovarian cancer: An extracted individual patient data and trial-level meta-analysis. Organization:Instituto do Câncer ...,University of São Pa...,Instituto D’Or de Pe...,Drug:PARPi,Target:poly (ADP-ribose) po...,Congress:ASCO 2023, Search all connections
Abstract Molecular and immune profiling of TP53-mutated ovarian cancers with non-BRCA1/2 homologous recombination gene alterations. Organization:Labcorp Oncology, Du...,Duke University Medi...,Duke Cancer Institut...,Drug:PD-L1, Search all connections
Abstract Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer. Organization:University of Ottawa,Ottawa, ON, Canada,OHRI,Drug:PARP inhibitors,niraparib,olaparib,Target:PARP, Search all connections
Abstract Understanding differences in the rates of BRCA/HRD testing and treatment in 1st line maintenance in patients with ovarian cancer treated by gynecologic oncologists compared to other providers: A quality initiative by Integra Connect (IC) PrecisionQ. Organization:South Carolina Oncol...,Integra Connect Prec...,Integra Connect,Drug:PARPi,Target:HRD,BRCA1,Congress:ASCO 2023, Search all connections
Abstract A phase 1 study of the SYK inhibitor fostamatinib and weekly paclitaxel for recurrent platinum-resistant ovarian cancer. Clinical trial:J1708,Organization:Johns Hopkins Sidney...,Sidney Kimmel Compre...,University of Pennsy..., Search all connections
Abstract Mechanisms of resistance to bispecific T-cell engager therapy for ovarian cancer. Organization:Massachusetts Genera...,Meigs Division of Gy...,Vincent Department o...,Drug:BiTE,Target:tumor-associated ant...,Congress:ASCO 2023, Search all connections
Abstract CD47 expression in ovarian cancer: Dynamic correlation with lymphocyte and macrophage features as well as thrombospondin-1 (TSP-1) under neoadjuvant chemotherapy. Clinical trial:GINECO-OV119,Organization:Gustave Roussy Cance...,INSERM U981 GUSTAVE ...,Groupe d'Investigate..., Search all connections
Abstract Anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib as front-line treatment for newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study (ALTER-GO-010). Organization:Jiangsu Province Hos...,Huai'an First People...,Nanjing Drum Tower H..., Search all connections
Abstract Patterns of ovarian cancer care in an elderly population in Australia: A prospective cohort study from the National Gynaecology Oncology Registry (NGOR). Organization:Monash University Sc...,Cancer Research Prog...,Peter MacCallum Canc...,Drug:platinum-based chemo..., Search all connections
Abstract Proactive assessment of patient reported outcomes in patients with ovarian cancer. Organization:12 de Octubre Univer...,Wollongong Hospital,Princess Margaret - ..., Search all connections
Abstract Trends in ovarian cancer incidence and incidence-based mortality: A 15-year population-based analysis. Organization:Stanford University ...,Palo Alto, CA,Congress:ASCO 2023, Search all connections
Abstract Anastomotic leakage following bowel resection in radical cytoreductive surgery for ovarian cancer: A subgroup analysis of the prospective AGO-OVAR.OP3/LION. Organization:Institute for Medica...,Coordinating Center ...,Department of Gyneco..., Search all connections
Abstract The effect of maintenance hormone therapy on overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study. Organization:Massachusetts Genera...,Meigs Division of Gy...,Vincent Department o...,Drug:Androgen deprivation...,Target:Estrogen Receptors (...,Progesterone recepto...,Congress:ASCO 2023, Search all connections
Abstract Efficacy and safety of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer who had measurable residual disease: A post-hoc subgroup analysis of the PRIME study. Organization:Qilu Hospital of Sha...,National Cancer Cent...,Cancer Hospital of t..., Search all connections
Abstract Germline variants in non-BRCA1/2 homologous recombination-related genes and ovarian cancer: Analysis of tumor phenotype and survival. Organization:Memorial Sloan Kette...,Department of Epidem...,Department of Medici...,Congress:ASCO 2023, Search all connections
Abstract Phase 2 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with granulosa cell ovarian cancer. Organization:Developmental Therap...,Biometric Research P...,Investigational Drug..., Search all connections
Abstract Ex vivo tumor testing platform for predicting clinical response to platinum-based therapy in patients with high grade serous ovarian cancer. Organization:Radboud University M...,Nijmegen,Netherlands Cancer I...,Drug:carboplatin, Search all connections
Abstract Safety and efficacy of PIPAC in ovarian cancer patients with peritoneal metastases: A first-in-US phase I study. Clinical trial:19184,Organization:City of Hope Nationa...,City of Hope Medical...,City of Hope Cancer ..., Search all connections
Abstract BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study. Organization:APHP-INSERM U1149 Un...,European Georges Pom...,Centre de Recherche ..., Search all connections
Abstract The role of innate immune system in modulating CHK1 inhibitor (CHK1i) response in BRCA wild-type (BRCAwt), platinum-resistant high-grade serous ovarian cancer (PR-HGSOC): Exploratory analysis from a phase II study of CHK1i prexasertib. Organization:Women’s Malignancies...,Center for Cancer Re...,National Cancer Inst...,Drug:prexasertib,CHK1i, Search all connections
Abstract DNA methylation patterns between tissue and blood samples in ovarian cancer. Organization:Department of Gyneco...,Department of Pathol...,Burning Rock Bioengi...,Congress:ASCO 2023, Search all connections
Abstract Analyses of tumor microenvironment affecting the survival in patients with ovarian cancer receiving intraperitoneal chemotherapy: Translational research from the phase 3 trial of intraperitoneal therapy for ovarian cancer with carboplatin (TRiPocc). Clinical trial:GOTIC-001/JGOG3019,Organization:Aichi Cancer Center ...,Cancer Science Insti...,National University ..., Search all connections
Abstract Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin as first-line treatment for Chinese patients with ovarian cancer: A multi‑center, randomized, open‑label trial. Organization:Women's Hospital Sch...,Qilu Hospital of Sha...,The First Affiliated..., Search all connections
Abstract Circulating tumor DNA (ctDNA) as a marker of residual disease and recurrence in resected stage I-IV epithelial ovarian cancer (EOC). Organization:Peter MacCallum Canc...,Epworth Healthcare,Western Health, Search all connections
Abstract Real-world data from a multi-center study: Insights to the efficacy and safety in patients with ovarian cancer (OC) received niraparib as first-line (1st-L) maintenance therapy (MT). Organization:Zhongda Hospital, So...,School of Medicine, ...,University of Scienc..., Search all connections
Abstract Utility of surgically documented minimal residual disease as a therapeutic target and early surrogate of frontline treatment outcomes in ovarian cancer. Clinical trial:2015-0520,Organization:University of Texas ...,University of Texas ...,Drug:bevacizumab,PARP inhibitors,Target:PARP,VEGF and c-MET pathw...,Congress:ASCO 2023, Search all connections
Abstract Nivolumab plus ipilimumab (N+I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Clinical trial:Pro00014171,Organization:Swedish Cancer Insti...,American Society of ...,Sutter Sacramento Me..., Search all connections
Abstract Venous thromboembolism prophylaxis during neoadjuvant chemotherapy for patients with ovarian cancer. Organization:University of Michig...,University of Michig...,Beaumont Health,Drug:pharmacologic VTE pr...,Target:venous thromboemboli...,Congress:ASCO 2023, Search all connections
Abstract Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance. Organization:Kliniken Essen-Mitte,Agomab Spain,Centre Jean Perrin, Search all connections
Abstract Systematic high-throughput combination drug screen to enhance poly (ADP-ribose) polymerase (PARP) inhibitor efficacy in ovarian cancer. Organization:The University of Te...,National Institute o...,Center for Translati..., Search all connections
Abstract Correlating expression of NaPi2b and FRa in high grade serous ovarian cancer (HGSOC). Organization:Sarah Cannon Researc...,Mary Crowley Cancer ...,Tennessee Oncology, ..., Search all connections
Abstract Phase 1 dose escalation study of SL-172154 (SIRPα-Fc-CD40L) in platinum-resistant ovarian cancer. Clinical trial:SL03-OHD-101,Organization:START Midwest, Grand...,City of Hope Compreh...,Stephenson Cancer Ce..., Search all connections
Abstract Association of HRD ovarian cancer by RAD51 with hot immune microenvironment: Translational analyses of MITO 16A/MaNGO-OV2 trial. Organization:University of Parma,Department of Molecu...,Federico II Universi..., Search all connections
Abstract XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers. Clinical trial:MER-XMT-1660-1,Organization:Sarah Cannon Researc...,Tennessee Oncology, ...,Summit Cancer Center..., Search all connections
Abstract Bevacizumab exposure and tumor response in patients with platinum resistant epithelial ovarian cancer. Clinical trial:2017-004197-34,Organization:Gustave Roussy Dépar...,La Timone University...,Sorbonne University ..., Search all connections
Abstract Modi-1, anti-citrullinated neoepitope vaccine, alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal, and ovarian cancers: ModiFy phase I/II basket clinical trial—Report after completion of monotherapy dose-finding. Clinical trial:Modi-1-001,Organization:The Clatterbridge Ca...,Department of Surger...,The Christie NHS Fou..., Search all connections
Abstract Prospective single-arm study of endocrine therapies with ovarian function suppression in premenopausal patients with node-positive early breast cancer with low genomic risk (INTERSTELLAR trial, KBCSG-25). Clinical trial:2021-1151-002,Drug:Ovarian-function sup...,Tamoxifen,aromatase inhibitor,Target:aromatase,Estrogen Receptor (E...,Organization:Gangnam Severance Ho...,Yonesi University Co..., Search all connections
Abstract Influence of ovarian function supression on quality of life in breast cancer survivors during adjuvant endocrine therapy. Organization:School of Medicine U...,Agency for Medicinal...,University Hospital ...,Drug:Tamoxifen,GnRHa, Search all connections
Abstract Real-world impact of TAILORx on chemotherapy use and SOFT/TEXT on ovarian function suppression uptake in a population based-cohort of women 40 years and under with HR-positive, HER2-negative, axillary lymph node negative breast cancer. Organization:Schulich School of M...,Department of Intern...,Western University,Drug:Cisplatin,Target:cell division, Search all connections
Abstract Efficacy of ovarian function suppression of 3-monthly versus monthly GnRH agonist as endocrine therapy for premenopausal breast cancer patients. Organization:Hospital Beneficênci...,Hospital Beneficênci...,Drug:goserelin,aromatase inhibitors,Tamoxifen,Target:Gonadotropin-releasi...,aromatase,Estrogen Receptor (E..., Search all connections
Abstract Impact of immune checkpoint inhibition on ovarian reserve in patients with melanoma enrolled in the ECOG-ACRIN E1609 adjuvant trial. Organization:Dana-Farber Cancer I...,Boston, MA,Brigham and Women's ..., Search all connections
Abstract Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC). Clinical trial:ZN-c3-002,Organization:Department of Medica...,Department of Invest...,Cabrini Research, Ma..., Search all connections
Abstract Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC). Clinical trial:VS-6766-201,Organization:The Royal Marsden NH...,National Cancer Rese...,University of Virgin..., Search all connections
Abstract Toxicity profile and discordance between patients/physicians regarding niraparib maintenance in recurrent ovarian cancer (ROC) patients: Lessons from the NIQOLE real-life study—GINECO study. Clinical trial:GINECO-OV239B,Organization:Department of Medica...,Centre François Bacl...,CHRU Besançon - Hôpi..., Search all connections
Abstract A phase II trial of palbociclib combined to letrozole after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer: LACOG 1018. Clinical trial:LACOG 1018,Organization:Hospital São Lucas d...,Hospital Fêmina - Gr...,Brazilian Gynecologi..., Search all connections
Abstract Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses. Clinical trial:NCI-2015-01910,Organization:Dana-Farber Cancer I...,Mayo Clinic,Harvard Medical Scho...,Drug:berzosertib, Search all connections
Abstract The Normal Risk Ovarian Screening Study (NROSS): Twenty-one year update. Organization:The UT MD Anderson C...,University of Texas ...,Unity Point Health, Search all connections
Abstract Trends in palliative care utilization among patients with ovarian cancer in the United States. Organization:Rutgers Robert Wood ...,Rutgers School of Pu...,Rutgers Cancer Insti...,Congress:ASCO 2024, Search all connections
Abstract Decision making factors regarding hospice care: A qualitative exploration in patients with recurrent ovarian cancer. Organization:The University of Te...,Congress:ASCO 2024, Search all connections
Abstract Monitoring ovarian function in oncology studies: Results and insights from the DeFi phase 3 study of nirogacestat in desmoid tumor. Drug:Nirogacestat,placebo,Target:gamma secretase,Organization:Clinical Research Di...,Fred Hutchinson Canc...,University of Washin..., Search all connections
Abstract A phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer (SCORES). Drug:Suvemcitug,paclitaxel,pegylated liposomal ...,Target:Topotecan,β-tubulin,Topoisomerase II, Search all connections
Abstract AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer. Organization:Caucasus Medical Cen...,Big Horn Basin Cance...,HINSDALE HOSPITAL,Clinical trial:AVB500-OC-004,Congress:ASCO 2024, Search all connections
Abstract Efficacy and safety of envafolimab plus lenvatinib combined with etoposide in recurrent ovarian, peritoneal, and fallopian tube cancer: An open-label, single-arm study—The ENLEN-OC-001 study. Drug:Envafolimab,lenvatinib,etoposide,Target:PD-L1,Lenvatinib (L),Topoisomerase II,Organization:The Affiliated Zhong...,Congress:ASCO 2024, Search all connections
Abstract Chemoresistance in high grade serous ovarian cancer molecular subtypes and the role of NRF2. Organization:Cooper Medical Schoo...,Baghdad Teaching Hos...,Cooper University He...,Congress:ASCO 2024, Search all connections
Abstract Identification of potential biomarkers with alternative splicing landscape of HIPEC-treated ovarian cancer: An RNAseq sub-analysis of a HIPEC clinical trial. Organization:Tgen,TGen/City of Hope Co...,Clinical trial:12316,Congress:ASCO 2024, Search all connections
Abstract Differences in clinical features between CA-125 and RECIST progression in patients with ovarian cancer treated with PARP inhibitors. Organization:Qilu Hospital of Sha...,Department of Obstet...,Congress:ASCO 2024, Search all connections
Abstract In-hospital outcomes of patients with ovarian cancer and venous thromboembolism: A Nationwide Inpatient Sample analysis. Organization:Brookly Hospital Cen...,Emanuel Cancer Cente...,Turlock,Congress:ASCO 2024, Search all connections
Abstract Unveiling primary platinum resistant ovarian cancer: Demographic and clinical perspectives from multicenter cancer registry in India. Organization:Christian Medical Co...,Institute Of Medical...,Amala Institute of M..., Search all connections
Abstract An open, prospective, single arm, phase II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) with neoadjuvant chemotherapy in patients with advanced ovarian cancer: Interim analysis from the AK104-IIT-003 study. Drug:AK104,Cadonilimab,Target:CTLA-4,PD-1,Organization:Hunan Cancer Hospita...,The Affiliated Cance...,Yunnan Cancer Hospit..., Search all connections
Abstract Neoadjuvant pamiparib in patients with newly diagnosed advanced ovarian cancer: A single-arm, prospective phase II trial. Drug:Pamiparib,paclitaxel,carboplatin,Target:Bevacizumab,paclitaxel,carboplatin, Search all connections
Abstract Real-world clinical outcomes and prognostic factors of olaparib maintenance in Korean patients with primary or recurrent high-grade ovarian cancer with exploratory analysis of location of BRCA1 and BRCA2 mutations. Organization:Songpa-Gu,Congress:ASCO 2024, Search all connections
Abstract Urinary-based detection of MSL, HE4, and CA125 as an additional dimension for predictive and prognostic modelling in ovarian cancer. Organization:Department of Gyneco...,Congress:ASCO 2024, Search all connections
Abstract Association of homologous recombination repair mutation defined with a 15-gene panel with the prognosis of epithelial ovarian cancer: A Chinese multicenter retrospective study. Drug:PARP inhibitors,Target:BRCA1,BRCA2,Organization:The Affiliated Zhong...,Zhejiang Cancer Hosp...,Department of Obstet...,Congress:ASCO 2024, Search all connections
Abstract Analysis of glycemia during olaparib therapy in patients with ovarian cancer. Drug:olaparib,Target:poly(ADP-ribose) pol...,Organization:University of Medica...,Congress:ASCO 2024, Search all connections
Abstract Disparities in the prevalence of acute pulmonary embolism in patients with ovarian cancer: A nationwide analysis. Organization:University of Missou...,School of Medicine, ...,Columbia, MO, Search all connections
Abstract Effect of circulating tumor cells (CTC) and CTC clusters with PD-L1 dynamic biomarker on cellular burden in patients with ovarian cancer. Organization:MIT-WPU, Pune, India,Congress:ASCO 2024, Search all connections
Abstract Development and validation of an efficacy assessment platform utilizing patient-derived xenograft (PDX) models in ovarian cancer research. Organization:Sungkyunkwan Univers...,Congress:ASCO 2024, Search all connections
Abstract Charlson’s comorbidity and remission outcomes in women diagnosed with epithelial ovarian cancer. Organization:Department of Resear...,Kaiser Permanente So...,MedHealth, Inc,Congress:ASCO 2024, Search all connections
Abstract First results of the NOGGO PERCEPTION: Phase II investigational study of pembrolizumab in combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer. Drug:pembrolizumab,carboplatin,pegylated liposomal ...,Target:PD-1,carboplatin,Topoisomerase II, Search all connections
Abstract Enhanced anti-ovarian cancer efficacy with MSLN-chimeric antigen receptor T cells secreting anti-CD39 antibody. Organization:OriCell Therapeutics,Shanghai Key Laborat...,Institute of Materna...,Congress:ASCO 2024, Search all connections
Abstract Overall survival and patterns of care for women with rare ovarian cancers: A prospective study from the Australian National Gynae-Oncology Registry (NGOR). Organization:Monash University Sc...,Mercy Hospital for W...,Monash University Sc...,Congress:ASCO 2024, Search all connections
Abstract Clinical features and prognostic analysis of 247 patients with ovarian clear cell carcinoma (OCCC) and an exploration of the treatment of recurrent OCCC: A single-center study in China. Organization:National Cancer Cent...,National Clinical Re...,Cancer Hospital, Chi...,Congress:ASCO 2024, Search all connections
Abstract A phase I/II study of maplirpacept in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer (OC): Phase 1 results. Drug:maplirpacept,doxorubicin,PLD,Target:CD47 on tumor cells,VEGF and c-MET pathw...,Organization:Pfizer Ltd.,Clinical trial:TTI-622-02, Search all connections
Abstract Overall survival in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance: Real-world data of the C-PATROL study. Drug:olaparib,Target:BRCA1,BRCA2,Organization:Med. Fakultät Mannhe...,Oncologic Medical Ce...,Hospital Aschaffenbu..., Search all connections
Abstract Weekly BH009 in patients with squamous cell carcinoma of the head and neck (SCCHN) and ovarian cancer: Interim phase I results. Drug:BH009,Taxotere,docetaxel,Target:docetaxel,tubulin,Organization:Affiliated Zhongshan...,Clinical trial:BH009-I-101,Congress:ASCO 2024, Search all connections
Abstract Multiomic analysis in ovarian clear cell carcinoma to gain insight into biology and therapeutic opportunities. Drug:trastuzumab deruxtec...,Organization:Portland,OR,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Leveraging genomic instability scores (GIS) to investigate BRCA variants of unknown significance (VUS) in ovarian cancer: An analysis of 14,513 patients in the Myriad Collaborative Research Registry (MCRR). Organization:Myriad Genetics Inc,Congress:ASCO 2024, Search all connections
Abstract Homologous recombination deficiency score for predicting efficacy of platinum-based chemotherapy and PARPi maintenance therapy in ovarian cancer. Organization:Huai'an Second Peopl...,Jiangsu simcere diag...,Congress:ASCO 2024, Search all connections
Abstract Use of Gynecologic Cancer Intergroup (GCIG) CA125 criteria to evaluate cell cycle checkpoint kinase 1 inhibitor (CHK1i) prexasertib response and disease progression (PD) in recurrent high-grade serous ovarian cancer (HGSOC). Drug:prexasertib,Organization:Statistical Consulti...,Computer and Statist...,Data Management Serv...,Congress:ASCO 2024, Search all connections
Abstract Deciphering the correlation between Chr3q26.2 amplification through homologous recombination deficiency and improved survival in ovarian cancer under platinum-based adjuvant therapy. Organization:Geneseeq Research In...,Congress:ASCO 2024, Search all connections
Abstract Liquid biopsy detection of structural variant breakpoints to monitor ovarian cancer clonal evolution. Organization:The University of Te...,Department of Genomi...,Congress:ASCO 2024, Search all connections
Abstract Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer. Drug:bevacizumab,cyclophosphamide,pembrolizumab,Target:Programmed cell deat...,VEGF and c-MET pathw...,Organization:University of Texas ...,The University of Te...,Congress:ASCO 2024, Search all connections
Abstract CRS-HIPEC following neo-adjuvant pressurized intraperitoneal aerosol chemotherapy (PIPAC) with systemic chemotherapy in primarily advanced inoperable epithelial ovarian cancer: An ISPSM collaborative study. Organization:Aster International ...,Congress:ASCO 2024, Search all connections
Abstract Relationship of cancer stem cell functional assay and objective response rate of patients with recurrent platinum-resistant ovarian cancer in a randomized trial. Drug:ChemoID,platinum-based treat...,Target:DNA,Organization:Kaiser Permanente Lo...,Charleston Area Medi...,LSU School of Medcn, Search all connections
Abstract Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A final overall survival analysis of a multicenter, open-label, randomized, phase 3 trial. Organization:Institute for Ovaria...,Congress:ASCO 2024, Search all connections
Abstract Upregulation of GREB1 in colorectal cancer ovarian metastases may be a potential therapeutic target. Organization:The Ohio State Unive...,The Ohio State Unive...,UC Irvine,Congress:ASCO 2024, Search all connections
Abstract Distinctive clinical and molecular aberrations of colorectal cancer patients with ovarian metastases. Organization:Vanderbilt Universit...,Vanderbilt-Ingram Ca...,Congress:ASCO 2024, Search all connections
Abstract Synergistic cytotoxicity of histone deacetylase, poly-ADP ribose polymerase inhibitors and decitabine in breast and ovarian cancer cells: Therapeutic implications. Drug:panobinostat,vorinostat,talazoparib,Target:decitabine (DAC, D),histone deacetylase ...,HDAC, Search all connections
Abstract AURKA blockage as a strategy to overcome resistance to olaparib and platinum in high-grade ovarian cancer (HGOC). Drug:olaparib,alisertib,Target:AURKA,PARP,Organization:Translational Oncolo...,La Paz University Ho...,Instituto de Investi..., Search all connections
Abstract Unraveling the role of ubiquitin C-terminal hydrolase L1 in high grade serous ovarian cancer pathogenesis. Drug:LDN-5744,carboplatin,Target:Ubiquitin C-terminal...,UCHL1,Organization:Women’s Oncology, Wo...,Department of Molecu...,Department of Pathob..., Search all connections
Abstract Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from the randomized phase II trial CHIVA (GINECO). Organization:CHU Saint-Etienne,EMR3738 Therapeutic ...,Lyon-Sud Hospital, Search all connections
Abstract Bevacizumab combination therapy versus standard chemotherapy for ovarian cancer in shorter and longer followup duration: A systematic review and meta-analysis of randomized controlled trials. Drug:bevacizumab,Target:VEGF and c-MET pathw...,Organization:Allama Iqbal Medical...,King Edward Medical ...,Fayoum University,Congress:ASCO 2024, Search all connections
Abstract Clinical and outcome patterns in epithelial ovarian cancer (EOC) within a Latin American cohort. Organization:Ninth of July Univer...,Instituto Nacional d...,Instituto Nacional d..., Search all connections
Abstract Sleep disturbance and fatigue in patients with ovarian cancer during chemotherapy and surgery compared to PARPi maintenance therapy. Organization:Cancer Support Commu...,Merck & Co., Inc.,Congress:ASCO 2024, Search all connections
Abstract A real-world, patient-reported outcomes study in patients with platinum-sensitive recurrent ovarian cancer receiving long-term maintenance therapy with niraparib. Organization:Henan Provincial Peo...,Guangzhou Women and ...,The Affiliated Cance...,Congress:ASCO 2024, Search all connections
Abstract Educating a diverse group of women in Los Angeles County on ovarian and uterine cancers and clinical trials. Organization:MiOra,Encino,Congress:ASCO 2024, Search all connections
Abstract Utilization of PARP inhibitors in the management of ovarian cancer in Nigeria. Organization:Holy Name Medical Ce...,Windsor University S...,State Specialist Hos...,Congress:ASCO 2024, Search all connections
Abstract Ethnic and clinical differences in gBRCA and HRD mutated breast and ovarian cancers and their response to PARP inhibitors. Organization:Sheikh Shakbout Medi...,Sheikh Shakhbout Med...,Congress:ASCO 2024, Search all connections
Abstract Germline landscape of ovarian cancer across age groups: Spotlight on elderly patients. Organization:New York, NY, Gyneco...,Congress:ASCO 2024, Search all connections
Abstract Association of a polygenic risk score with risk of abnormal ultrasound findings and ovarian cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Organization:National Cancer Inst...,American Cancer Soci...,National Institutes ...,Congress:ASCO 2024, Search all connections
Abstract Impact of the oral contraceptive pill on the rate of ovarian cancer incidence in different races of women. Organization:HCA Florida Brandon ...,Comprehensive Hemato...,Congress:ASCO 2024, Search all connections
Abstract Efficacy and safety of luveltamab tazevibulin vs investigator’s choice of chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC) expressing folate receptor alpha (FRα): The REFRaME-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study. Drug:luveltamab tazevibul...,Gemcitabine,paclitaxel,Target:FRα,Topoisomerase II,DNA, Search all connections
Abstract Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage III and IV ovarian cancer after interval cytoreductive surgery (FOCUS). Drug:Cisplatin,bevacizumab,PARP inhibitors,Target:PARP,VEGF and c-MET pathw...,DNA,Organization:Biomedical Statistic...,Department of Obstet..., Search all connections
Abstract Repurposing atovaquone as a STAT3 inhibitor for the treatment of platinum resistant ovarian cancer. Drug:atovaquone,Target:STAT3,Organization:Emory Winship Cancer...,Emory Winship Cancer...,Clinical trial:STUDY00005363,Congress:ASCO 2024, Search all connections
Abstract Randomized pilot study assessing the safety and tolerability hyperthermic intraperitoneal chemotherapy (HIPEC) at completion of interval cytoreductive surgery or chemotherapy the day prior to interval cytoreductive surgery for patients with stage III/IV ovarian cancer undergoing neoadjuvant chemotherapy. Drug:Cisplatin,carboplatin,paclitaxel,Target:paclitaxel,VEGF and c-MET pathw...,DNA,Organization:Ohio State Universit..., Search all connections
Abstract Open-label, phase 2 study of adebrelimab combined with fuzuloparib in the treatment of patients with HRD-positive, recurrent platinum-resistant ovarian cancer. Drug:Adebrelimab,fuzuloparib,niraparib,Target:PD-1,PD-L1,PARP,Organization:Clinical Oncology Sc..., Search all connections
Abstract A phase II study evaluating the effect of IMNN-001 on second-look laparoscopy (SLL) when administered in combination with bevacizumab (BEV) and neoadjuvant chemotherapy (NACT) in patients newly diagnosed with advanced epithelial ovarian cancer (EOC). Drug:IMNN-001,carboplatin,paclitaxel,Target:PARP2,carboplatin,interleukin-12 (IL-1..., Search all connections
Abstract Phase II clinical trial of PLX038 in patients with platinum resistant ovarian, primary peritoneal and fallopian tube cancer. Drug:Irinotecan,PLX038,SN-38,Target:TOP1,DNA topoisomerase I ...,DNA topoisomerase II,Organization:Mayo Clinic Cancer C..., Search all connections
Abstract REJOICE-Ovarian01: A phase 2/3 study of raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer (OVC). Drug:R-DXd,bevacizumab,Mirvetuximab soravta...,Target:folate receptor alph..., Search all connections
Abstract A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer. Drug:Ubamatamab,cemiplimab,Target:Muc16CD,PD-1,CD3,Organization:Lyon University Hosp...,Gustave Roussy, Dépa...,Peter MacCallum Canc..., Search all connections
Abstract A phase IV trial to confirm the efficacy of olaparib in combination with bevacizumab as maintenance frontline treatment of HRD-positive ovarian tumours (IOlanTHe). Drug:olaparib,bevacizumab,Target:VEGF (Vascular Endot...,PARP,Organization:Humanitas University...,Unit of Gynaecologic...,University of Milan-..., Search all connections
Abstract A randomized, multicenter, open-label phase III trial of hyperthermic intraperitoneal chemotherapy in platinum-resistant recurrent ovarian cancer (KOV-HIPEC-02). Drug:Cisplatin,doxorubicin,mitomycin C,Target:Mitomycin,doxorubicin,DNA,Organization:Inje University Busa...,Seoul St Mary’s Hosp..., Search all connections
Abstract Phase I/II study of TROP2 CAR engineered IL15-transduced cord blood-derived NK cells delivered intraperitoneally for the management of platinum resistant ovarian cancer, mesonephric-like adenocarcinoma, and pancreatic cancer. Drug:TROP2-CAR/IL-15,Target:TROP2,Organization:The University of Te...,Department of Invest...,Department of Stem C...,Clinical trial:2022-0687,Congress:ASCO 2024, Search all connections
Abstract Study on the efficacy and toxicity of pamiparib combined with tamoxifen in the treatment of patients with epithelial ovarian cancer with biochemical recurrence during first-line PARPi maintenance therapy. Drug:Tamoxifen,Pamiparib,Target:PARP2,Estrogen Receptor (E...,PARP1,Organization:Department of Gyneco...,State Key Laboratory...,Collaborative Innova..., Search all connections
Abstract SB221: A proof-of-concept study to assess the combination of SON-1010 (IL12-FHAB) and atezolizumab in patients with platinum-resistant ovarian cancer. Drug:SON-1010,Atezolizumab,IL-12,Target:IL-12,FcRn,GP60, Search all connections
Abstract Disparities in ovarian and uterine cancer in relation to the development of novel therapeutics. Drug:novel ovarian cancer...,novel uterine cancer...,Target:clear cell carcinoma,novel ovarian cancer...,serous carcinoma,Organization:California Pacific M...,University of Califo..., Search all connections
Abstract Characterization of ESR1 mutations in endometrial and ovarian cancers. Organization:Sidney Kimmel Compre...,Johns Hopkins Univer...,Baltimore, MD, Search all connections
Abstract Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer: FLORA-4 study. Drug:Oregovomab,niraparib,Target:STING (stimulator of...,CA125,Organization:Department of OB/GYN,Duke Cancer Institut...,CanariaBio, Inc,Clinical trial:QPT-ORE-005, Search all connections
Abstract Efficacy of niraparib in patients with advanced ovarian cancer: A meta-analysis of randomized controlled trials. Drug:niraparib,Target:poly-adenosine dipho...,Organization:Federal University o...,Rio De Janeiro,Faculdade Santa Marc..., Search all connections
Abstract Characterization of long-term survivors from four clinical trials examining patients with folate receptor alpha–positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine. Drug:Mirvetuximab soravta...,Mirvetuximab soravta...,bevacizumab,Target:folate receptor-alph...,PARP,VEGF and c-MET pathw...,Organization:University Hospital ..., Search all connections
Abstract Germline genetic profiles of women with ovarian malignancies: A Myriad Collaborative Research Registry study. Organization:University of Califo...,Congress:ASCO 2024, Search all connections
Abstract Targeting the CD47/TSP-1 axis: A promising strategy for patients with ovarian cancer (OC) that relapses on PARP inhibitors (PARPi). Drug:TAX2,PARPi,olaparib,Target:BRCA2,TSP-1,CD47 on tumor cells, Search all connections
Abstract Phase II study of pembrolizumab and lenvatinib in platinum sensitive recurrent ovarian cancer. Drug:pembrolizumab,lenvatinib,Target:PD-1,Lenvatinib (L),Organization:Department of Physio...,Department of Physio...,Clinical trial:7405-20,Congress:ASCO 2024, Search all connections
Abstract Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) trial: Mirvetuximab soravtansine (MIRV) vs. investigator’s choice chemotherapy (ICC) in older patients with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRα) expression. Drug:Mirvetuximab soravta...,paclitaxel,pegylated liposomal ...,Target:folate receptor alph...,tubulin,topoisomerase I, Search all connections
Abstract Molecular and immune characterization of squamous cell ovarian cancers for identification of therapeutic targets. Organization:Rutgers Robert Wood ...,Congress:ASCO 2024, Search all connections
Abstract Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic ovarian cancer: Results from a multi-center multi-country phase 1/2a expansion cohort. Drug:23ME-00610,Target:CD200R1,Organization:Cohen Children's Med...,Clinical trial:23ME-00610-CLIN-001,Congress:ASCO 2024, Search all connections
Abstract Intratumoral Ral-binding protein 1 (RalBP1) expression as a potential predictor of bevacizumab treatment efficacy in patients with ovarian cancer. Drug:bevacizumab,RalBP1,Target:VEGF and c-MET pathw...,RalBP1,Organization:Department of Obstet...,Klinikum der Univers...,Congress:ASCO 2024, Search all connections
Abstract Artificial intelligence to predict homologous recombination deficiency in ovarian cancer from whole-slide histopathological images. Organization:Institut de Cancerol...,Saint-Herblain,France, Search all connections
Abstract An evaluation of cell-free tumor DNA from 20 mL of peritoneal fluid for homologous recombination deficiency (HRD) testing in newly diagnosed ovarian cancer (OC). Organization:Gustave Roussy Insti...,Villejuif, France,France, Search all connections
Abstract Role of the receptor for advanced glycation end products (RAGE) in blood as a potential biomarker for progression to olaparib: A post hoc analysis of patients with platinum-resistant ovarian cancer (PROC) treated in the ROLANDO-GEICO 1601 trial. Drug:olaparib,pegylated liposomal ...,Target:PARP2,Topoisomerase II,PARP1,Organization:Department of Medica...,Laboratory of Transl...,Cancer Center Clínic..., Search all connections
Abstract Evaluation of prognostic and predictive values of bespoke circulating tumor DNA assay in patients with advanced epithelial ovarian cancer. Drug:PARPi,bevacizumab,Target:VEGF and c-MET pathw...,PARP1,Organization:BGI Genomics,BGI-Shenzhen,Tianjin Medical Labo..., Search all connections
Abstract Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Survival outcomes and immune correlates. Drug:carboplatin,paclitaxel,durvalumab,Target:CTLA-4,microtubules,Programmed death-lig..., Search all connections
Abstract Association of physical activity with self-reported quality of life after primary chemotherapy for ovarian cancer. Organization:University of Texas ...,Congress:ASCO 2024, Search all connections
Abstract Real-world biomarker testing, treatment patterns and outcomes in a US cohort of patients with advanced ovarian cancer. Drug:olaparib,bevacizumab,Target:Vascular Endothelial...,poly(ADP-ribose) pol...,Organization:AstraZeneca Pharmace...,Congress:ASCO 2024, Search all connections
Abstract A phase II study of anlotinib plus albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or peritoneal carcinomar (A-Plus trial): Updated efficacy and safety. Drug:Anlotinib,albumin-bound paclit...,ab-paclitaxel,Target:microtubules,anlotinib,tubulin,Organization:Sun Yat-sen Universi..., Search all connections
Abstract Beacon: A phase II study of bevacizumab, atezolizumab, and cobimetinib in patients with recurrent, platinum resistant, high grade serous ovarian cancer. Drug:bevacizumab,Atezolizumab,cobimetinib,Target:MEK1,PDL1,VEGF and c-MET pathw...,Organization:The Royal Women’s Ho...,Cancer Immunology Re..., Search all connections
Abstract Anlotinib plus hormone therapy in patients with platinum-resistant recurrent ovarian cancer: A prospective, single-arm, open-label, phase II study. Drug:Anlotinib,letrozole,Target:tyrosine kinase,Estrogen Receptor (E...,VEGF and c-MET pathw...,Organization:Xin Hua Hospital, Af...,Renji Hospital, Shan...,Congress:ASCO 2024, Search all connections
Abstract Feasibility of using the handheld MasSpec pen technology for intraoperative identification of ovarian cancer during tumor reductive surgery. Organization:Department of Gyneco...,University of Texas ...,Congress:ASCO 2024, Search all connections
Abstract Hospital challenges faced by frail patients with ovarian cancer and the adverse outcomes: A nationwide study. Organization:Upstate Medical Univ...,Brooklyn, NY,Nuvance Health/Vassa..., Search all connections
Abstract Systematic review of frailty assessment in ovarian cancer studies. Organization:Library and Informat...,Congress:ASCO 2024, Search all connections
Abstract PROTA: A phase I clinical trial combining an oncolytic adenovirus encoding for TNFa and IL-2 with pembrolizumab for the treatment of platinum-resistant or -refractory ovarian cancer. Drug:pembrolizumab,TILT-123,pegylated liposomal ...,Target:IL-2,TNFa,Programmed death rec...,Organization:TILT Biotherapeutics, Search all connections
Abstract Overall survival (OS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance monotherapy: Update from the L-MOCA trial. Drug:olaparib,Target:BRCA1,BRCA2,Organization:Department of Gyneco...,Department of Gyneco...,Department of Gyneco..., Search all connections
Abstract The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study. Drug:RC88,monomethyl auristati...,bevacizumab,Target:mesothelin,PARP,VEGF and c-MET pathw..., Search all connections
Abstract Characterizing FOLR1 expression in low-grade serous ovarian carcinoma. Organization:Hoag Memor Hosp,Congress:ASCO 2024, Search all connections
Abstract Final safety results from ATHENA–MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer. Drug:rucaparib,placebo,Target:rucaparib,Placebo,Organization:GOG Foundation,National Cancer Cent...,Hospital Universitar..., Search all connections
Abstract A phase I single-arm, open-label trial of engineering tumor-infiltrating lymphocytes with membrane-bound IL-7 for recurrent ovarian cancer. Organization:Department of Obstet...,Shanghai Juncell The...,Department of Radiol...,Clinical trial:GC203-1.0,Congress:ASCO 2024, Search all connections
Abstract The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings? Drug:bevacizumab,Target:Vascular Endothelial...,Organization:GSK,Flatiron Health, San...,Congress:ASCO 2024, Search all connections
Abstract Consistent data about the predictive factors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers in two large independent datasets. Organization:Centre Hospitalier L...,GINECO, Paris,Fondazione Policlini..., Search all connections
Abstract Efficacy, safety, and biomarkers of neoadjuvant niraparib monotherapy in homologous recombination deficiency (HRD) advanced ovarian cancer: A prospective, multicenter, phase II, single-arm NANT study. Drug:niraparib,Target:PARP,Organization:Department of Gyneco...,Department of Gyneco...,Department of Gyneco..., Search all connections
Abstract Using artificial intelligence-powered evidence-based molecular decision-making for improved outcomes in ovarian cancer. Organization:Predictive Oncology,Congress:ASCO 2024, Search all connections
Abstract Evaluation of a novel extracellular vesicle (EV) based ovarian cancer (OC) screening test in asymptomatic postmenopausal women. Organization:Mercy BioAnalytics, ...,MRC Clinical Trials ...,Congress:ASCO 2024, Search all connections
Abstract Neoadjuvant combination treatment of olaparib and pembrolizumab for patients with HRD-positive advanced ovarian cancer. Drug:olaparib,pembrolizumab,Target:PD-1,PARP,Organization:Department of Medica...,Department of Obstet...,Department of Gyneco..., Search all connections
Abstract Pelvic ultrasound-based deep learning models for accurate diagnosis of ovarian cancer: Retrospective multicenter study. Organization:Aemasue Corperation,Korean University Me...,Anam hospital,Congress:ASCO 2024, Search all connections
Abstract Gemcitabine plus cisplatin in recurrent ovarian, fallopian tube, and primary peritoneal cancer. Drug:Gemcitabine,Cisplatin,Target:ribonucleotide reduc...,ribonucleotide reduc...,DNA,Organization:The University of Te...,Congress:ASCO 2024, Search all connections
Abstract Tumor-informed ctDNA as an objective marker for postoperative residual disease in epithelial ovarian cancer. Organization:Klinikum Starnberg,SAGA Diagnostics AB,Congress:ASCO 2024, Search all connections
Abstract Differences in physical and emotional distress amongst patients undergoing neoadjuvant chemotherapy versus surgery for advanced ovarian cancer: Patient-reported outcomes at diagnosis. Organization:Mayo Clinic,Rochester, MN,Congress:ASCO 2024, Search all connections
Abstract Use of cell-free DNA from ascites to identify variants and tumour evolution in a cohort of patients with advanced ovarian cancer. Organization:The Royal Hospital f...,Congress:ASCO 2024, Search all connections
Abstract Efficacy and safety of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors: Clinical data from advanced cervical cancer and platinum-resistant recurrent ovarian cancer cohorts. Drug:PM8002,Target:PD-L1,VEGF-A,Organization:Shanxi Province Canc...,Jiangsu Cancer Hospi...,The First Affiliated..., Search all connections
Abstract Value of ctDNA-based molecular residual disease (MRD) in evaluating the adjuvant therapy effect in ovarian cancer. Organization:Shenzhen Center,Congress:ASCO 2024, Search all connections
Abstract Unveiling the unique identity of clear-cell endometrial cancer (CCEC): A comprehensive comparative analysis with ovarian counterpart and other endometrial subtypes. Organization:Service de Génétique...,Congress:ASCO 2024, Search all connections
Abstract A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors. Drug:CUSP06,Target:CDH6,Organization:Virginia Cancer Spec...,Stephenson Cancer Ce...,OnCusp Therapeutics,...,Congress:ASCO 2024, Search all connections
Abstract Clinicopathologic and genomic characteristics of patients with advanced ovarian, breast, and prostate cancer treated with poly (ADP-ribose) polymerase inhibitors (PARPi) in a real-world setting. Drug:PARPis,Target:PARP2,PARP1,Organization:Cleveland Clinic Bru...,Center for Immunothe...,Congress:ASCO 2024, Search all connections
Abstract Comprehensive molecular profiling of newly diagnosed advanced, high-grade ovarian cancer: Unveiling BRCA1/2 mutations and genomic instability scores to advocate for public insurance coverage of genetic testing—Insights from the Hellenic Society of Medical Oncology (HeSMO) national program. Drug:PARP inhibitors,Target:PARP,Organization:Hellenic Society of ...,Congress:ASCO 2024, Search all connections
Abstract A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer. Drug:NC410,pembrolizumab,Target:collagen,LAIR-1,PD-1,Organization:Merck and Co Inc,NextCure Inc,Clinical trial:NC410-02, Search all connections
Abstract Current diagnostic guidelines and perpetuation of inequities in ovarian cancer: A National Cancer Database study. Organization:University of Pennsy...,University of Pennsy...,Congress:ASCO 2024, Search all connections
Abstract A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009. Organization:Georgetown Lombardi ...,Georgetown Universit...,MedStar Health, Search all connections
Abstract Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A). Organization:AstraZeneca,Sidney Kimmel Compre...,Dana-Farber Cancer I...,Drug:Ceralasertib,olaparib,Target:ATR,PARP,Clinical trial:827744, ESR-16-12311, Search all connections
Abstract Menopausal hormone therapy and ovarian and endometrial cancers: Long-term follow-up of the Women’s Health Initiative randomized trials. Organization:The Lundquist Resear...,Division of Public H...,Fred Hutchinson Canc..., Search all connections
Abstract Omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy: The CARACO phase III randomized trial. Organization:Nantes Université,CRCI2NA,UMR 1307 Inserm-UMR ..., Search all connections
Abstract Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study. Organization:GEICO,Arcagy-Gineco,NSGO-CTU, Search all connections
Abstract Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas. Organization:Lifespan Cancer Inst...,Rhode Island Hospita...,Providence, RI, Search all connections
Abstract Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial. Organization:Princess Margaret Ca...,University Health Ne...,Toronto, ON, Canada, Search all connections
Abstract Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: The CHIPOR randomized phase III trial. Organization:Centre Léon Bérard,Centre Paul Papin,Lorraine Cancer Inst..., Search all connections
Abstract Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up. Organization:Biometrics Departmen...,Department of Gyneco...,Sint Antonius Hospit..., Search all connections
Abstract Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. Organization:University of Milan-...,University of Califo...,European Institute o..., Search all connections
Abstract Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. Organization:Agomab Spain,LMU Munich,The Jikei University..., Search all connections
Abstract Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort. Organization:Vall d’Hebron Instit...,Vall d'Hebron Univer...,The Ohio State Unive..., Search all connections
Abstract Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018). Organization:HonorHealth Research...,Duke Cancer Institut...,Chaim Sheba Medical ..., Search all connections
Abstract Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials. Organization:University of Oxford,Centre for Public He...,Karolinska Institute..., Search all connections
Abstract https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.5505 Clinical trial:VB-111-701/GOG-3018,Indication:Ovarian Cancer,Product:paclitaxel + ofraner...,Paclitaxel,Drug:Tiragolumab,Ofranergene obadenov..., Search all connections
Abstract https://www.nejm.org/doi/full/10.1056/NEJMoa2309169 Clinical trial:IMGN853-0416,Indication:Ovarian Cancer,Product:Mirvetuximab Soravta...,Drug:Mirvetuximab soravta..., Search all connections
Abstract https://www.abstractsonline.com/pp8/#!/10517/presentation/20251 Indication:Ovarian Cancer,Product:ACR-368,Drug:prexasertib,Target:CHEK1,CHEK2, Search all connections